NZ622652B2 - [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 - Google Patents

Abstract

Provided are [1,2,3]triazolo[4,5-d]pyrimidine derivative compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include (S)-1-(5-tert-butyl-3-((1-cyclopropyl-1H-tetrazol-5-yl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)-3-methylpyrrolidin-3-ol and (R)-1-[5-tert-Butyl-3-(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol. The compounds are agonists of cannabinoid receptor 2. pyrrolidin-3-ol and (R)-1-[5-tert-Butyl-3-(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol. The compounds are agonists of cannabinoid receptor 2.

Description

F. nn-La Roche AG, 0 Basle, Switzerland Case: 30705 [1,2,3] TRIAZOLO [4,5-D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 The present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in ular to compounds that are preferential agonists of the Cannabinoid Receptor 2. The compound of formula (I) is particularly useful in the treatment or prophylaxis of e.g. pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial tion, ic sis, l injury, burning, hypertrophic scars, keloids, itis pyrexia, liver cirrhosis or tumors, regulation of bone mass, neurodegeneration, stroke, ent ischemic attack or uveitis.

The invention relates in particular to a compound of formula (I) R1 A N N R2 (I) wherein A is alkyl, hydroxyalkyl, O)-, -C(O)-, -SO2- or absent; R1 is hydrogen, alkyl, haloalkyl, hydroxyl, alkoxy, haloalkoxy, phenyl, halophenyl, alkoxyphenyl, haloalkylphenyl, haloalkoxyphenyl, (halo)(haloalkyl)phenyl, cyanophenyl, hydroxyalkoxyphenyl, alkylsulfonylphenyl, alkylsulfonylaminophenyl, cyano, cycloalkyl, cycloalkylalkoxy, amino, sulfonyl)(alkyl)[1,2,4]triazolyl, (halo)(dialkylamino)pyridinyl, DP/08.10.12 (alkyl)(oxy)pyridinyl, nitro-benzo[1,2,5]oxadiazolylaminopyridinyl, heterocyclyl, alkylheterocyclyl, hydroxyheterocyclyl, alkylheterocyclyl, heteroaryl, haloheteroaryl, alkylheteroaryl, lkylheteroaryl or haloalkylheteroaryl, wherein cyclyl is a three to eight membered carbocyclic ring comprising at least one nitrogen or oxygen atom, and wherein heteroaryl is pyridinyl, pyrazolyl, oxadiazolyl, furazanyl, tetrazolyl or triazolyl; R2 is halogen or -NR3R4 or -OR5; one of R3 and R4 is hydrogen or alkyl and the other one is alkyl or cycloalkyl; or R3 and R4 together with the nitrogen atom to which they are attached form heterocyclyl or substituted heterocyclyl, wherein heterocyclyl is morpholinyl, piperidinyl, zinyl, pyrrolidinyl, 2-oxaazaspiro[3.3]heptyl, inyl, thiazolidinyl, thiomorpholinyl, dioxothiomorpholinyl, oxazepanyl, 6- azaspiro[3.4]octyl, 6-oxaazaspiro[3.3]heptyl, 2-oxaaza-spiro[3.4]octyl, isoxazolidinyl, aziridinyl, dioxoisothiazolidinyl or oxopyrolidinyl and wherein substituted heterocyclyl is heterocyclyl substituted with one to four substituents independently selected from alkyl, halogen, yl, alkoxy, hydroxyalkyl, carboxyl, alkoxyalkyl, cyano, alkylamino, dialkylamino, alkylcarbonylamino, alkylcarbonyl(alkylamino), , carbonyl, aminoalkyl, alkylpyrazolyl or alkylisoxazolyl; R5 is alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl or oxetanyl; or a ceutically acceptable salt or ester thereof; with the proviso that 3-[(2-chlorophenyl)methyl](1,1-dimethylethyl)(4- morpholinyl)-3H-1,2,3-triazolo[4,5-d]pyrimidine and N-cyclopropyl(1,1- dimethylethyl)(phenylmethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidinamine are excluded.

The cannabinoid receptors are a class of cell membrane receptors belonging to the G n-coupled receptor superfamily. There are currently two known subtypes, termed Cannabinoid Receptor 1 (CB1) and Cannabinoid Receptor 2 (CB2). The CB1 or is mainly expressed in the central nervous (i.e. amygdala cerebellum, hippocampus) system and to a lesser amount in the periphery. CB2, which is encoded by the CNR2 gene, is mostly expressed peripherally, on cells of the immune system, such as macrophages and T-cells (Ashton, J. C. et al. Curr Neuropharmacol 2007, 5(2), 73-80; Miller, A. M. et al. Br J Pharmacol 2008, 153(2), 299-308; Centonze, D., et al. Curr Pharm Des 2008, 14(23), 2370-42), and in the gastrointestinal system (Wright, K. L. et al. Br J Pharmacol 2008, 153(2), 263-70). The CB2 receptor is also widely distributed in the brain where it is found primarily on microglia and not neurons (Cabral, G. A. et al. Br J Pharmacol 2008, 153(2): 240-51).

The st in CB2 receptor agonists has been ly on the rise during the last decade (currently 30-40 patent applications/year) due to the fact that several of the early compounds have been shown to have cial effects in pre-clinical models for a number of human diseases including chronic pain (Beltramo, M. Mini Rev Med Chem 2009, 9(1), 11-25), atherosclerosis (Mach, F. et al. J Neuroendocrinol 2008, 20 Suppl 1, 53-7), tion of bone mass (Bab, I. et al. Br J Pharmacol 2008, 153(2), 182-8), neuroinflammation (Cabral, G. A. et al. J Leukoc Biol 2005, 78(6), 1192-7), ischemia/reperfusion injury (Pacher, P. et al. Br J Pharmacol 2008, 153(2), 252-62), systemic fibrosis tshina, A. et al. tis Rheum 2009, 60(4), 1129-36; Garcia- Gonzalez, E. et al. tology (Oxford) 2009, 48(9), 1050-6), liver fibrosis (Julien, B. et al. Gastroenterology 2005, 128(3), 742-55; Munoz-Luque, J. et al. J Pharmacol Exp Ther 2008, 324(2), 475-83). ia/reperfusion (I/R) injury is the principal cause of tissue damage occurring in conditions such as stroke, myocardial infarction, cardiopulmonary bypass and other vascular surgeries, and organ transplantation, as well as a major mechanism of end-organ damage complicating the course of atory shock of various etiologies. All these conditions are characterized by a disruption of normal blood supply ing in an insufficient tissue oxygenation. Re-oxygenation e.g., reperfusion is the ultimate treatment to restore normal tissue oxygenation. However the absence of oxygen and nutrients from blood creates a condition in which the restoration of circulation results in further tissue . The damage of usion injury is due in part to the inflammatory response of damaged tissues. White blood cells, carried to the area by the newly returning blood, release a host of inflammatory factors such as interleukins as well as free radicals in response to tissue damage. The restored blood flow reintroduces oxygen within cells that damages cellular proteins, DNA, and the plasma membrane.

Remote ischemic preconditioning (RIPC) represents a strategy for harnessing the body’s endogenous protective lities against the injury incurred by ischemia and reperfusion. It describes the intriguing phenomenon in which transient non-lethal ischemia and usion of one organ or tissue confers resistance to a subsequent episode of “lethal” ischemia reperfusion injury in a remote organ or tissue. The actual mechanism through which transient ischemia and reperfusion of an organ or tissue confers protection is currently unknown gh several hypotheses have been ed.

The humoral hypothesis proposes that the endogenous substance (such as ine, bradykinin, opioids, CGRP, endocannabinoids, Angiotensin I or some other as yet unidentified humoral ) generated in the remote organ or tissue enters the blood stream and activates its respective receptor in the target tissue and thereby recruiting the various intracellular pathways of protection implicated in ischemicpreconditioning.

Recent data indicates that endocannabinnoids and their receptors, in particular CB2 might be involved in pre-conditioning and contribute to prevent reperfusion injury by downregulation of the inflammatory se (Pacher, P. et al. Br J Pharmacol 2008, 153(2), 252-62). Specifically, recent studies using CB2 tool agonists demonstrated the efficacy of this concept for ng the I/R injury in the heart (Defer, N. et al. Faseb J 2009, 23(7), 2120-30), the brain (Zhang, M. et al. J Cereb Blood Flow Metab 2007, 27(7), 1387-96), the liver (Batkai, S. et al. Faseb J 2007, 21(8), 1788-800) and the kidney (Feizi, A. et al. Exp Toxicol Pathol 2008, ), ).

Moreover, over the last few years, a growing body of literature tes that CB2 can also be of interest in sub-chronic and chronic setting. ic upregulation of CB1 and CB2 has been shown to be associated in animal models of chronic diseases associated with fibrosis (Garcia-Gonzalez, E. et al. Rheumatology (Oxford) 2009, 48(9), 1050-6; Yang, Y. Y. et al. Liver Int 2009, 29(5), 678-85) with a relevant expression of CB2 in myofibroblasts, the cells responsible for fibrosis progression.

Activation of CB2 receptor by selective CB2 agonist has in fact been shown to exert anti-fibrotic effect in diffuse systemic sclerosis (Garcia-Gonzalez, E. et al. Rheumatology (Oxford) 2009, 48(9), ) and CB2 receptor has emerged as a critical target in experimental dermal fibrosis (Akhmetshina, A. et al. tis Rheum 2009, 60(4), 1129- 36) and in in liver pathophysiology, including fibrogenesis associated with chronic liver diseases (Lotersztajn, S. et al. Gastroenterol Clin Biol 2007, 31(3), 255-8; Mallat, A. et al.

Expert Opin Ther Targets 2007, 11(3), 403-9; Lotersztajn, S. et al. Br J Pharmacol 2008, 153(2), 286-9).

The compounds of the invention bind to and modulate the CB2 receptor and have lower CB1 receptor activity.

In the present description the term “alkyl”, alone or in combination, signifies a straight-chain or ed-chain alkyl group with 1 to 8 carbon atoms, particularly a straight or branched-chain alkyl group with 1 to 6 carbon atoms and more particularly a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straightchain and branched-chain C1-C8 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric , the isomeric heptyls and the isomeric octyls, particularly methyl, ethyl, propyl, butyl and pentyl more particularly methyl, ethyl, propyl, isopropyl, isobutyl, butyl and isopentyl. Particular examples of alkyl are methyl, ethyl and pentyl, in particular methyl and ethyl.

The term “cycloalkyl”, alone or in combination, signifies a lkyl ring with 3 to 8 carbon atoms and particularly a cycloalkyl ring with 3 to 6 carbon atoms. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, eptyl and cyclooctyl. Particular “cycloalkyl” are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. A particular example of cycloalkyl is cyclohexyl.

The term “alkoxy”, alone or in combination, signifies a group of the formula alkyl-O- in which the term "alkyl" has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.butoxy and tert.butoxy, particularly methoxy.

The term “oxy”, alone or in combination, signifies the -O- group.

The terms “halogen” or “halo”, alone or in combination, signifies fluorine, chlorine, e or iodine and particularly fluorine, chlorine or bromine, more particularly fluorine and chlorine. The term “halo”, in combination with r group, denotes the tution of said group with at least one halogen, particularly substituted with one to five halogens, particularly one to four halogens, i.e. one, two, three or four halogens. Particular halogens are fluorine, e and chlorine, more particularly fluorine and chlorine.

The term “haloalkyl”, alone or in combination, denotes an alkyl group substituted with at least one halogen, ularly substituted with one to five halogens, particularly one to three halogens. Particular “haloalkyl” are trifluoromethyl and trifluoropropyl. A particular lkyl” is trifluoromethyl.

The term “haloalkoxy”, alone or in combination, denotes an alkoxy group substituted with at least one n, particularly substituted with one to five halogens, particularly one to three halogens. A particular “haloalkoxy” is trifluoromethoxy.

The term henyl”, alone or in combination, denotes a phenyl group substituted with at least one n, particularly substituted with one to three halogens. Particular “halophenyl” are chlorophenyl, chlorofluorophenyl, dichlorophenyl, bromophenyl and chlorodifluorophenyl.

The terms “hydroxyl” and “hydroxy”, alone or in combination, signify the -OH group.

The term “carbonyl”, alone or in combination, signifies the -C(O)- group.

The term “amino”, alone or in ation, signifies the primary amino group (-NH 2), the secondary amino group (-NH-), or the tertiary amino group (-N-).

The term “sulfonyl”, alone or in combination, signifies the -SO2- group.

The term “pharmaceutically acceptable salts” refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, oric acid, particularly hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, c acid, oxalic acid, maleic acid, c acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, enesulfonic acid, salicylic acid, N-acetylcystein. In addition these salts may be prepared form addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts. Salts derived from c bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally ing substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins. The compound of formula (I) can also be present in the form of rions. Particularly preferred pharmaceutically acceptable salts of compounds of formula (I) are the salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and methanesulfonic acid.

"Pharmaceutically acceptable esters" means that compounds of general formula (I) may be derivatised at functional groups to e tives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl , methylthiomethyl esters and yloxymethyl esters.

Additionally, any physiologically acceptable equivalents of the compounds of general formula (I), r to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention.

If one of the starting als or nds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protecting groups (as described e.g. in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wuts, 3rd Ed., 1999, Wiley, New York) can be introduced before the al step applying s well known in the art. Such protecting groups can be removed at a later stage of the synthesis using standard s described in the literature. Examples of protecting groups are tert-butoxycarbonyl (Boc), 9-fluorenylmethyl carbamate (Fmoc), 2-trimethylsilylethyl carbamate (Teoc), carbobenzyloxy (Cbz) and p-methoxybenzyloxycarbonyl (Moz).

The compound of formula (I) can n several asymmetric centers and can be present in the form of optically pure enantiomers, es of enantiomers such as, for example, racemates, es of diastereoisomers, diastereoisomeric racemates or mixtures of reoisomeric racemates.

The term “asymmetric carbon atom” means a carbon atom with four different substituents. According to the Cahn-Ingold-Prelog Convention an asymmetric carbon atom can be of the “R” or “S” configuration.

In the definition of R1, examples of three to eight membered carbocyclic ring comprising at least one en or oxygen atom are morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, 2-oxaazaspiro[3.3]heptyl, azetidinyl, 3,3-difluoroazetidinyl, 3- hydroxyazetindyl, 3-methoxyazetidinyl, thiazolidinyl, thiomorpholinyl, dioxothiomorpholinyl, oxazepanyl, 2-oxaazaspiro[3.4]octyl, 6-oxa azaspiro[3.3]heptyl, 2-oxaaza-spiro[3.4]octyl, aziridinyl, dioxoisothiazolidinyl, oxetanyl, 3-alkyl-oxetanyl, rooxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinonyl, pyrrolidinonyl, dinonyl, dioxothiazetidinyl, dioxothiazetidinyl, dioxo thiazinanyl, hydroxypyrrolidinyl and difluorpyrrolidinyl; In the definition of R1, particular examples of three to eight ed carbocyclic ring comprising at least one nitrogen or oxygen atom are morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, azetidinyl, 3,3-difluoroazetidinyl, 3-hydroxyazetindyl, 3- methoxyazetidinyl, thiomorpholinyl, dioxothiomorpholinyl, dioxoisothiazolidinyl, oxetanyl, 3-alkyl-oxetanyl, 3-fluorooxetanyl, tetrahydrofuranyl and pyrrolidinonyl; In the definition of R1, particular examples of three to eight membered carbocyclic ring comprising at least one nitrogen or oxygen atom are morpholinyl, piperidinyl, azetidinyl, 3,3-difluoroazetidinyl, 3-methoxyazetidinyl, thiomorpholinyl, dioxothiomorpholinyl, oxetanyl, l-oxetanyl and pyrrolidinonyl: In the tion of R1, further particular examples of three to eight membered carbocyclic ring comprising at least one nitrogen or oxygen atom are morpholinyl and 2- oxaazaspiro[3.3]heptyl.

In the tion of R1, cyclyl is advantageously oxetanyl, tetrahydrofuranyl, 1,1-dioxo-thietanyl or 1,1-dioxo-tetrahydrothiophenyl.

In the definition of R5: alkyl is advantageously methyl, ethyl, isopropyl or pentyl; cycloalkyl is advantageously cyclopropyl, cyclobutyl or cyclopentyl, in particular cyclobutyl orcyclopentyl; cycloalkylalkyl is advantageously cyclopropylalkyl or cyclopropylethyl; haloalkyl is advantageously trifluoropropyl.

The invention relates in particular to a compound of formula (I) wherein: A is alkyl, hydroxyalkyl, -CH2C(O)-, -C(O)-, -SO2- or absent; R1 is hydrogen, alkyl, haloalkyl, hydroxyl, alkoxy, haloalkoxy, phenyl, halophenyl, alkoxyphenyl, kylphenyl, haloalkoxyphenyl, cyanophenyl, hydroxyalkoxyphenyl, alkylsulfonylphenyl, alkylsulfonylaminophenyl, cyano, cycloalkyl, cycloalkylalkoxy, amino, heterocyclyl, alkylheterocyclyl, yheterocyclyl, alkylheterocyclyl, heteroaryl or teroaryl, wherein heterocyclyl is a three to eight membered carbocyclic ring comprising at least one nitrogen or oxygen atom, and wherein heteroaryl is pyridinyl, pyrazolyl, oxadiazolyl or furazanyl; R2 is halogen or -NR3R4; one of R3 and R4 is hydrogen or alkyl and the other one is alkyl or cycloalkyl; or R3 and R4 er with the nitrogen atom to which they are attached form heterocyclyl or substituted heterocyclyl, wherein heterocyclyl is morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, 2-oxaazaspiro[3.3]heptyl, azetidinyl, thiazolidinyl, thiomorpholinyl, dioxothiomorpholinyl, oxazepanyl, 2-oxa azaspiro[3.4]octyl, 6-oxaazaspiro[3.3]heptyl, 2-oxaaza-spiro[3.4]octyl, isoxazolidinyl, aziridinyl or sothiazolidinyl and wherein substituted cyclyl is heterocyclyl substituted with one to four substituents independently selected from alkyl, halogen, yl, alkoxy, hydroxyalkyl, yl, alkoxyalkyl and cyano; or a pharmaceutically able salt or ester thereof; with the proviso that 3-[(2-chlorophenyl)methyl](1,1-dimethylethyl)(4- morpholinyl)-3H-1,2,3-triazolo[4,5-d]pyrimidine and N-cyclopropyl(1,1- dimethylethyl)(phenylmethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidinamine are excluded.

The ion relates in ular to the following: A compound of formula (I) wherein A is -CH2-, -CH2CH 2-, -CH(CH3)-, -CH(OH)CH 2-, -CH2C(O)-, -C(O)-, -SO2- or absent; A compound of formula (I) n A is alkyl or hydroxyalkyl; A compound of formula (I) wherein A is -CH2-, -CH2CH 2-, -CH(CH3)- or )CH 2-; A compound of formula (I) wherein R1 is hydrogen, alkyl, haloalkyl, hydroxyl, alkoxy, phenyl, halophenyl, alkoxyphenyl, haloalkylphenyl, haloalkoxyphenyl, alkylsulfonylphenyl, henyl, cycloalkyl, alkylheterocyclyl, hydroxyheterocyclyl, heteroaryl, cycloalkylheteroaryl, haloheteroaryl or alkylheteroaryl, wherein heterocyclyl is a carbocyclic ring containing at least one nitrogen atom and wherein heteroaryl is pyridinyl, pyrazolyl, oxadiazolyl, tetrazolyl or furazanyl; A compound of formula (I) wherein R1 is hydrogen, alkyl, haloalkyl, hydroxyl, alkoxy, phenyl, enyl, alkoxyphenyl, haloalkylphenyl, haloalkoxyphenyl, cyanophenyl, cycloalkyl, alkylheterocyclyl, hydroxyheterocyclyl, heteroaryl or haloheteroaryl, wherein heterocyclyl is morpholinyl or 2-oxaazaspiro[3.3]heptyl, and wherein heteroaryl is pyridinyl, pyrazolyl or oxadiazolyl; A compound of formula (I) wherein R1 is haloalkyl, phenyl, halophenyl, haloalkylphenyl, cyanophenyl, alkylsulfonylphenyl, cycloalkyl, heteroaryl, cycloalkylheteroaryl, teroaryl or alkylheteroaryl, n heteroaryl is pyridinyl, pyrazolyl, oxadiazolyl, tetrazolyl or furazanyl. A compound of formula (I) wherein R1 is haloalkyl, , halophenyl, haloalkylphenyl, henyl, cycloalkyl or aryl, wherein heteroaryl is pyridinyl, pyrazolyl or oxadiazolyl; A compound of formula (I) wherein R1 is hydrogen, methyl, methoxy, hydroxyl, chlorophenyl, henyl, methoxyphenyl, trifluoromethoxyphenyl, chlorofluorophenyl, cyclohexyl, rophenyl, trichlorophenyl, hydroxyethoxyphenyl, dichlorofluorophenyl, (chloro)(trifluoromethyl)phenyl, (dichloro)(trifluoromethyl)phenyl, methylsulfonylphenyl, methylsulfonylaminophenyl, pyridinyl, chloropyridinyl, ropyridinyl, methylpyrrolidinyl, oxetanyl, methyloxetanyl, (methylsulfonyl)(methyl)[1,2,4]triazolyl, (chloro)(dimethylamino)pyridinyl, l)(oxy)pyridinyl, nitrobenzo [1,2,5]oxadiazolylaminopyridinyl, lyl, methylpiperidinyl, morpholinyl, 2-oxa- 6-azaspiro[3.3]heptyl, hydroxypyrrolidinyl, trifluoromethyl, difluorophenyl, oromethylphenyl, cyanophenyl, phenyl, tetrahydrofuranyl, methyl-[1,2,4]oxadiazolyl, furazanyl, methylfurazanyl, methyl-[1,3,4]oxadiazolyl, -[1,3,4]oxadiazolyl, methyltetrazolyl, methyl-[1,2,4]triazolyl, dimethyl-[1,2,4]triazolyl, trifluoromethylpyrazolyl, dimethylpyrazolyl, -[1,2,3]triazolyl, trifluoromethyl- [1,2,4]oxadiazolyl, cyclopropyltetrazoly or methylfurazanyl; A compound of formula (I) wherein R1 is hydrogen, methyl, methoxy, hydroxyl, phenyl, bromophenyl, yphenyl, trifluoromethoxyphenyl, chlorofluorophenyl, cyclohexyl, dichlorophenyl, hydroxyethoxyphenyl, dichlorofluorophenyl, methylsulfonylphenyl, methylsulfonylaminophenyl, pyridinyl, chloropyridinyl, dichloropyridinyl, methylpyrrolidinyl, oxetanyl, methyloxetanyl, pyrazolyl, methylpiperidinyl, morpholinyl, 2-oxaazaspiro[3.3]heptyl, hydroxypyrrolidinyl, trifluoromethyl, chlorodifluorophenyl, trifluoromethylphenyl, henyl, , tetrahydrofuranyl, methyl-[1,2,4]oxadiazolyl or nyl; A compound of formula (I) wherein R1 is hydrogen, methyl, methoxy, hydroxyl, chlorophenyl, bromophenyl, methoxyphenyl, trifluoromethoxyphenyl, chlorofluorophenyl, cyclohexyl, dichlorophenyl, pyridinyl, chloropyridinyl, pyrazolyl, furazanyl, methylpiperidinyl, morpholinyl, 2-oxaazaspiro[3.3]heptyl, hydroxypyrrolidinyl, trifluoromethyl, chlorodifluorophenyl, trifluoromethylphenyl, cyanophenyl or phenyl; A compound of formula (I) wherein R1 is haloalkyl, phenyl, enyl, haloalkylphenyl, cyanophenyl, ulfonylphenyl, cycloalkyl, heteroaryl, cycloalkylheteroaryl, haloheteroaryl or alkylheteroaryl, wherein heteroaryl is pyridinyl, pyrazolyl, oxadiazolyl, tetrazolyl or furazanyl; A compound of formula (I) n wherein R1 is chlorophenyl, cyclohexyl, dichlorophenyl, pyridinyl, chloropyridinyl, dichloropyridinyl, trifluoromethyl, chlorodifluorophenyl, trifluoromethylphenyl, cyanophenyl, phenyl, methylsulfonylphenyl, methyltetrazolyl, methylfurazanyl or cyclopropyltetrazolyl; A compound of formula (I) wherein R1 is chlorophenyl, cyclohexyl, rophenyl, pyridinyl, trifluoromethyl, chlorodifluorophenyl, trifluoromethylphenyl, cyanophenyl or phenyl; A compound of formula (I) wherein R1 is chlorophenyl, methylfurazanyl, chloropyridinyl, methylsulfonylphenyl or methyltetrazolyl; A compound of formula (I) wherein R2 is -NR3R4; A compound of formula (I) wherein one of R3 and R4 is hydrogen or ethyl and the other one is ethyl or exyl; A nd of formula (I) wherein R3 and R4 together with the nitrogen atom to which they are ed form heterocyclyl or substituted heterocyclyl, wherein heterocyclyl is piperidinyl, piperazinyl, pyrrolidinyl, linyl, lidinyl, thiomorpholinyl, dioxo-thiomorpholinyl, oxazepanyl, 2-azetidinyl, 2-oxa azaspiro[3.3]heptyl, rolidinyl, 2-oxaazaspiro[3.4]octyl, 6-oxa ro[3.3]heptyl, isoxazolidinyl, aziridinyl, dioxoisothiazolidinyl, 2-oxaor azaspiro[3.4]octyl, and n substituted heterocyclyl is heterocyclyl substituted with one to four substituents independently selected from alkyl, halogen, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl, cyano, alkylamino, dialkylamino, alkylcarbonylamino, arbonyl(alkylamino), phenyl, aminoalkyl, methylpyrazolyl and methylisoxazolyl; A compound of formula (I) wherein R3 and R4 together with the nitrogen atom to which they are attached form heterocyclyl or substituted heterocyclyl, wherein heterocyclyl is piperidinyl, idinyl or azetidinyl, and wherein substituted heterocyclyl is heterocyclyl substituted with one to four substituents independently selected from alkyl, halogen, hydroxyl, hydroxyalkyl and alkoxyalkyl; A compound of formula (I) wherein R3 and R4 together with the nitrogen atom to which they are attached form piperidinyl, pyrrolidinyl, difluoropiperidinyl, difluoropyrrolidinyl, difluoroazetidinyl, (methyl)(hydroxyl)azetidinyl, hydroxypyrrolidinyl, hydroxymethylpyrrolidinyl, (hydroxymethyl)(difluoro)pyrrolidinyl, (hydroxyl)(difluoro)pyrrolidinyl, (hydroxyl)(hydroxymethyl)pyrrolidinyl, tetrafluoropyrrolidinyl, 2-oxaazaspiro[3.3]heptyl, methoxymethylpyrrolidinyl, methylpiperazinyl,morpholinyl, azetidinyl, yazetidinyl, methoxyazetidinyl, dimethylmorpholinyl, methylmorpholinyl, hydroxymethylmorpholinyl, thiazolidinyl, thiomorpholinyl, dioxothiomorpholinyl, oxazepanyl, dimethylpyrrolidinyl, methoxypyrrolidinyl, methylpyrrolidinyl, hydroxypiperidinyl, (hydroxyl)(hydroxymethyl)pyrrolidinyl, (methyl)(hydroxyl)pyrrolidinyl, 2-oxa azaspiro[3.4]octyl, 6-oxaazaspiro[3.3]heptyl, fluoropyrrolidinyl, isoxazolidinyl, inyl, (cyano)(fluoro)pyrrolidinyl, dioxo-isothiazolidinyl, cyanopyrrolidinyl, 2-oxa azaspiro[3.4]octyl, dihydroxypyrrolidinyl, rolidinyl, methylaminopyrrolidinyl, dimethylaminopyrrolidinyl, methylcarbonylaminopyrrolidinyl, methylcarbonyl(methylaminopyrrolidinyl), phenylpyrrolidinyl, methylcarbonyl(ethylaminopyrrolidinyl), methoxycarbonylazetidinyl, aminomethylpyrrolidinyl, methylpyrazolyl-pyrrolidinyl, methylisoxazolyl-pyrrolidinyl or methyl[1,2,4]oxadiazolyl-pyrrolidinyl; A compound of formula (I) wherein R3 and R4 together with the nitrogen atom to which they are attached form piperidinyl, pyrrolidinyl, difluoropiperidinyl, difluoropyrrolidinyl, difluoroazetidinyl, (methyl)(hydroxyl)azetidinyl, hydroxypyrrolidinyl, hydroxymethylpyrrolidinyl, (hydroxymehthyl)(difluoro)pyrrolidinyl, (hydroxyl)(difluoro)pyrrolidinyl, (hydroxyl)(hydroxymethyl)pyrrolidinyl, tetrafluoropyrrolidinyl, 2-oxaazaspiro[3.3]heptyl, methoxymethylpyrrolidinyl, methylpiperazinyl,morpholinyl, azetidinyl, yazetidinyl, methoxyazetidinyl, dimethylmorpholinyl, methylmorpholinyl, hydroxymethylmorpholinyl, thiazolidinyl, thiomorpholinyl, hiomorpholinyl, oxazepanyl, dimethylpyrrolidinyl, methoxypyrrolidinyl, methylpyrrolidinyl, hydroxypiperidinyl, xyl)(hydroxymethyl)pyrrolidinyl, (methyl)(hydroxyl)pyrrolidinyl, 2-oxa azaspiro[3.4]octyl, 1-azaspiro[3.3]heptyl, fluoropyrrolidinyl, isoxazolidinyl, aziridinyl, (cyano)(fluoro)pyrrolidinyl, dioxo-isothiazolidinyl, cyanopyrrolidinyl, 2-oxa azaspiro[3.4]octyl or dihydroxypyrrolidinyl; A compound of formula (I) n R3 and R4 together with the nitrogen atom to which they are attached form piperidinyl, pyrrolidinyl, ropiperidinyl, difluoropyrrolidinyl, difluoroazetidinyl, (methyl)(hydroxyl)azetidinyl, hydroxypyrrolidinyl, hydroxymethylpyrrolidinyl, tetrafluoropyrrolidinyl, 2-oxa azaspiro[3.3]heptyl, methoxymethylpyrrolidinyl, methylpiperazinyl,morpholinyl, inyl, hydroxyazetidinyl, methoxyazetidinyl, dimethylmorpholinyl, morpholinyl, hydroxymethylmorpholinyl, thiazolidinyl, rpholinyl, dioxothiomorpholinyl, oxazepanyl, dimethylpyrrolidinyl, methoxypyrrolidinyl, methylpyrrolidinyl, hydroxypiperidinyl, (hydroxyl)(hydroxymethyl)pyrrolidinyl, (methyl)(hydroxyl)pyrrolidinyl, 2-oxaazaspiro[3.4]octyl, 6-oxaazaspiro[3.3]heptyl, fluoropyrrolidinyl, olidinyl, aziridinyl, (cyano)(fluoro)pyrrolidinyl, dioxoisothiazolidinyl , cyanopyrrolidinyl, (hydroxyl)(hydroxymethyl)pyrrolidinyl, 2-oxa azaspiro[3.4]octyl or oxypyrrolidinyl; A compound of formula (I) wherein R3 and R4 together with the nitrogen atom to which they are attached form difluoropiperidinyl, difluoropyrrolidinyl, difluoroazetidinyl, (methyl)(hydroxyl)azetidinyl, hydroxypyrrolidinyl, hydroxymethylpyrrolidinyl, tetrafluoropyrrolidinyl, methoxymethylpyrrolidinyl, (hydroxyl)(hydroxymethyl)pyrrolidinyl or (methyl)(hydroxyl)pyrrolidinyl; A compound of formula (I) wherein R3 and R4 together with the en atom to which they are attached form heterocyclyl or substituted heterocyclyl, wherein heterocyclyl is piperidinyl, pyrrolidinyl, inyl or 2-oxaazaspiro[3.3]heptyl, and wherein substituted heterocyclyl is heterocyclyl substituted with one to four substituents independently selected from alkyl, n, hydroxyl, hydroxyalkyl and alkoxyalkyl; A compound of formula (I) wherein R3 and R4 together with the nitrogen atom to which they are attached form ropiperidinyl, ropyrrolidinyl, roazetidinyl, (methyl)(hydroxyl)azetidinyl, hydroxypyrrolidinyl, ymethylpyrrolidinyl, tetrafluoropyrrolidinyl, methoxymethylpyrrolidinyl, (hydroxyl)(hydroxymethyl)pyrrolidinyl, (methyl)(hydroxyl)pyrrolidinyl or 2-oxa azaspiro[3.3]heptyl; A compound of formula (I) wherein R2 is hydroxypyrrolidinyl or methylhydroxypyrrolidinyl, in particular hydroxypyrrolidinyl; and A nd of formula (I) wherein R5 is methyl, ethyl, isopropyl, pentyl, cyclobutyl, cyclopentyl, cyclopropylmehtyl, ropylethyl, trifluoropropyl or oxetanyl.

In the definition of R1, halophenyl, alkylfurazanyl, halopyridinyl, ulfonylphenyl and alkyltetrazolyl are particularly advantagerous, and halophenyl and alkyltetrazolyl are more particularly advantageous.

In the definition of R1, chlorophenyl, methylfurazanyl, chloropyridinyl, methylsulfonylphenyl and methyltetrazolyl are particularly advantageous, and chlorophenyl and methyltetrazolyl are more particularly advantageous.

It is particularly advantageous that R2 is -NR3R4 and that R3 and R4 together with the nitrogen atom to which they are attached form hydroxypyrrolidinyl.

It is particularly advantageous that A is alkyl, more ularly -CH2-.

The invention therefore also relates to the following advantageous embodiment: A compound of formula (I) wherein: A is alkyl; R1 is halophenyl, alkylfurazanyl, halopyridinyl, alkylsulfonylphenyl or alkyltetrazolyl; and R2 is -NR3R4 and R3 and R4 together with the en atom to which they are ed form hydroxypyrrolidinyl.

The invention further relates to the following advantageous embodiment: A compound of formula (I) wherein: A is -CH2-; R1 is chlorophenyl, methylfurazanyl, chloropyridinyl, methylsulfonylphenyl or methyltetrazolyl; and R2 is -NR3R4 and R3 and R4 together with the nitrogen atom to which they are attached form hydroxypyrrolidinyl.

The invention further relates to the following advantageous embodiment: A nd of a (I) wherein: A is alkyl; R1 is halophenyl or alkyltetrazolyl; and R2 is -NR3R4 and R3 and R4 together with the nitrogen atom to which they are attached form hydroxypyrrolidinyl.

The invention further s to the following advantageous embodiment: A compound of formula (I) wherein: A is -CH2-; R1 is chlorophenyl or tetrazolyl; and R2 is -NR3R4 and R3 and R4 together with the nitrogen atom to which they are attached form hydroxypyrrolidinyl.

The invention further relates in particular to a compound of formula (I) selected from -tert-butyl(2-chlorobenzyl)(piperidinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-butyl(2-chlorobenzyl)(4,4-difluoropiperidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-butyl(2-chlorobenzyl)(4-methylpiperazinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-butyl(2-chlorobenzyl)(pyrrolidinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-butyl(2-chlorobenzyl)(3,3-difluoropyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-butyl(2-chlorobenzyl)-N-ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinamine; -butyl(2-chlorobenzyl)-N-cyclohexyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinamine; -tert-butyl(2-chlorobenzyl)-N,N-diethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinamine; 6-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)oxa azaspiro[3.3]heptane; tidinyl)tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-butyl(2-chlorobenzyl)(3,3-difluoroazetidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)azetidinol; 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylazetidinol; -tert-butyl(2-chlorobenzyl)(3-methoxyazetidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; (2S,6R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-2,6- dimethylmorpholine; 4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylmorpholine; (4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholin yl)methanol; 3-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)thiazolidine; 4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)thiomorpholine; -tert-butyl(2-chloro-benzyl)(1,1-dioxo-1λ6-thiomorpholinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; ert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-1,4- oxazepane; 4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-2,2- dimethylmorpholine; 4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-3,3- dimethylmorpholine; -tert-butyl(2-chlorobenzyl)((2R,5R)-2,5-dimethylpyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidin- 3-ol; (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidin- 3-ol; 5-tert-butyl(2-chlorobenzyl)(3-methoxypyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-butyl(2-chlorobenzyl)(2,2-dimethylpyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-butyl(2-chlorobenzyl)(2-methylpyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 6-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)oxa azaspiro[3.4]octane; 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)piperidinol; (5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)piperidin- 3-ol; (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)piperidin- 3-ol; 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)oxa azaspiro[3.3]heptane; (S)tert-butyl(2-chlorobenzyl)(3-fluoropyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; (R)-(1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinyl)methanol; (S)-(1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidin- 2-yl)methanol; 2-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholine; 2-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)isoxazolidine; 7-(aziridinyl)tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; (R)tert-butyl(2-chlorobenzyl)(3-fluoropyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-butyl(2-chlorobenzyl)(3,3,4,4-tetrafluoropyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (R)tert-butyl(2-chlorobenzyl)(2-(methoxymethyl)pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (S)tert-butyl(2-chlorobenzyl)(2-(methoxymethyl)pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; )(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) fluoropyrrolidinecarbonitrile; 5-tert-butyl(2-chloro-benzyl)(1,1-dioxo-1λ6-isothiazolidin yl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholin yl)methanol; (5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinecarbonitrile; (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinecarbonitrile; (2S,3S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) xymethyl)pyrrolidinol; (2S,3R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) (hydroxymethyl)pyrrolidinol; 5-tert-Butyl(2-chloro-benzyl)(2-oxaaza-spiro[3.4]octyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]methylpyrrolidinol (3R,4R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidine-3,4-diol; (3S,4R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidine-3,4-diol; 4-(5-tert-butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholine; 4-(5-tert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholine; 5-tert-Butyl(2-chlorofluoro-benzyl)morpholinyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methoxy-ethyl)-3H-[1,2,3]triazolo[4,5- midine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl]- ethanol; -tert-Butylcyclohexylmethyl(3,3-difluoro-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(3-chloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(4-chloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(2,3-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2,4-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2,5-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2,6-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H-[1,2,3]triazolo[4,5- midine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H-[1,2,3]triazolo[4,5- midine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,2,2-trifluoro-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-4,5-difluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-3,6-difluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 3-(2-Bromo-benzyl)tert-butyl(3,3-difluoro-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-trifluoromethyl-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(3,3-difluoro-pyrrolidinyl)(2-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-trifluoromethoxy-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin ylmethyl]-benzonitrile; -tert-Butyl(3,3-difluoro-pyrrolidinyl)phenethyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] phenyl-ethanone; -tert-Butyl[(R)(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- ]triazolo[4,5-d]pyrimidine; 5-tert-Butyl[(S)(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] phenyl-ethanol; -tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- ]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)oxetanyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; and [5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl]-(2- chloro-phenyl)-methanone.

The invention further relates in particular to a compound of formula (I) selected from (3S,5R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl] hydroxymethyl-pyrrolidinol; {(R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-4,4- difluoro-pyrrolidinyl}-methanol; (R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-4,4- difluoro-pyrrolidinol; 5-tert-Butyl(2,6-dichlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(3-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2,5-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,6-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(4-methyl-furazanylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-methyl-[1,2,4]oxadiazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl[2-(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -Butyl[2-(3-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl[2-(4-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (S)[5-tert-Butyl(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinol; -tert-Butyl(2-chloro-benzenesulfonyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(R)-tetrahydro-furanyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(S)-tetrahydro-furanyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl](2- chloro-phenyl)-ethanone; -tert-Butyl(2,3-dichlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methanesulfonyl-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-pyridinyl-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-methyl-oxetanylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; ert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl](3- chloro-phenyl)-ethanone; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl](4- chloro-phenyl)-ethanone; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] pyridinyl-ethanone; ert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] pyridinyl-ethanone; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,3,6-trichloro-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chlorotrifluoromethyl-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-pyridinyl-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-pyridinyl-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2,3-dichlorotrifluoromethyl-benzyl)(3,3-difluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,4-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(1,1-dioxo-1λ6-thietanyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(1,1-dioxo-tetrahydro-1λ6-thiophenyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] pyridinyl-ethanone; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(5-methyl-[1,3,4]oxadiazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(5-methyl-[1,2,4]oxadiazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(1-methyl-1H-tetrazolylmethyl)-3H- ]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methyl-2H-[1,2,4]triazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(5-methanesulfonylmethyl-4H- [1,2,4]triazolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin ylmethyl]chloro-pyridinyl}-dimethyl-amine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-trifluoromethyl-1H-pyrazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; (S)[5-tert-Butyl(4-methyl-furazanylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; (S)[5-tert-Butyl(3-methyl-[1,2,4]oxadiazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(3-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; (S)[5-tert-Butyl(3,6-dichloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; [5-tert-Butyl(2,3-dichloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinol; (S)[5-tert-Butyl(2-trifluoromethyl-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- idinol; (S)[5-tert-Butyl(2-methanesulfonyl-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,5-dimethyl-2H-pyrazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-methyl-3H-[1,2,3]triazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(4,5-dimethyl-4H-[1,2,4]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methyloxy-pyridinylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (S)[5-tert-Butyl(3,4-dichloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(5-methyl-[1,2,4]oxadiazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(5-methyl-[1,3,4]oxadiazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2-methyl-2H-[1,2,4]triazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2,5-dimethyl-2H-pyrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-trifluoromethyl-[1,2,4]oxadiazol yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)(3,3-difluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; (S){5-tert-Butyl[2-(7-nitro-benzo[1,2,5]oxadiazolylamino)-pyridinylmethyl]- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl}-pyrrolidinol; )[5-tert-Butyl(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl] hydroxymethyl-pyrrolidinol; (S)[5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2,5-dimethyl-2H-[1,2,4]triazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2-methyloxy-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,5-dimethyl-2H-[1,2,4]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; (2S,3S)[5-tert-Butyl(4-methyl-furazanylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(3-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- midinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(2-methanesulfonyl-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(2-methyl-2H-[1,2,4]triazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(2-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; -tert-Butyl(4-methyl-furazanylmethyl)(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3-methyl-[1,2,4]oxadiazolylmethyl)(3,3,4,4-tetrafluoro-pyrrolidin yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(5-methyl-[1,3,4]oxadiazolylmethyl)(3,3,4,4-tetrafluoro-pyrrolidin yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)(3,3,4,4-tetrafluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)(3,3,4,4-tetrafluoropyrrolidinyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)(3,3,4,4-tetrafluoro-pyrrolidin yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(4-methyl-furazanylmethyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3-methyl-[1,2,4]oxadiazolylmethyl)(2-oxaaza-spiro[3.3]hept yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(5-methyl-[1,3,4]oxadiazolylmethyl)(2-oxaaza-spiro[3.3]hept yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(1-methyl-1H-tetrazolylmethyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)(2-oxaaza-spiro[3.3]hept yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)(2-oxaaza-spiro[3.3]hept- 6-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)(2-oxaaza-spiro[3.3]hept yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(2-methanesulfonyl-benzyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3-chloro-pyridinylmethyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidin one; -tert-Butyl(2-chloro-benzyl)(3,3-dimethyl-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; {1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidin- 3-yl}-methyl-amine; {1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidin- 3-yl}-dimethyl-amine; N-{(S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-acetamide; N-{(R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-acetamide; N-{1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-N-methyl-acetamide; -Butyl(2-chloro-benzyl)(3-phenyl-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; N-{1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-N-ethyl-acetamide; 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-azetidine carboxylic acid methyl ester; -tert-Butyl(2-chloro-benzyl)(3-methyl-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; C-{(S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-methylamine; -tert-Butyl(2-chloro-benzyl)[2-(1-methyl-1H-pyrazolyl)-pyrrolidinyl]-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-benzyl)[2-(2-methyl-2H-pyrazolyl)-pyrrolidinyl]-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(2-chloro-benzyl)[2-(3-methyl-isoxazolyl)-pyrrolidinyl]-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-benzyl)[2-(3-methyl-[1,2,4]oxadiazolyl)-pyrrolidinyl]- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidin -tert-Butyl(2-chloro-benzyl)cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-benzyl)(oxetanyloxy)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-benzyl)methoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-benzyl)ethoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(2-chloro-benzyl)isopropoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-benzyl)cyclopropylmethoxy-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(2-chloro-benzyl)(1-cyclopropyl-ethoxy)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -Butyl(2-chloro-benzyl)cyclopentyloxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-benzyl)(2,2-dimethyl-propoxy)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(2-chloro-benzyl)(2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-benzyl)((S)-2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)((R)-2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (3S)(3-benzyltert-butyl-triazolo[4,5-d]pyrimidinyl)pyrrolidinol; 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol; (R)(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)pyrrolidinol; 1-(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)pyrrolidinol; (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol; (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol; (S)(5-tert-butyl(2-(trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 3-methylpyrrolidinol; (R)(5-tert-butyl(2-(trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 3-methylpyrrolidinol; (S)(5-tert-butyl(2-(methylsulfonyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 3-methylpyrrolidinol; (R)(5-tert-butyl(2-(methylsulfonyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 3-methylpyrrolidinol; (5-tert-butyl((3-chloropyridinyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)methylpyrrolidinol; (R)(5-tert-butyl((3-chloropyridinyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)methylpyrrolidinol; (S)(5-tert-butyl((5-methyl-1,3,4-oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (R)(5-tert-butyl((5-methyl-1,3,4-oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (S)(5-tert-butyl((3-methyl-1,2,4-oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5- midinyl)methylpyrrolidinol; (R)(5-tert-butyl((3-methyl-1,2,4-oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (S)(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (R)(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (S)(5-tert-butyl((4-methyl-1,2,5-oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (R)(5-tert-butyl((4-methyl-1,2,5-oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (S)(5-tert-butyl(3,3,3-trifluoropropyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol; (R)(5-tert-butyl(3,3,3-trifluoropropyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol; (5-tert-butyl((1-cyclopropyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; and (R)(5-tert-butyl((1-cyclopropyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol.

The invention relates in particular to a compound of formula (I) selected from 5-tert-Butyl(2-chlorobenzyl)(4,4-difluoropiperidinyl)-3H-[1,2,3]triazolo[4,5- midine; -tert-Butyl(2-chlorobenzyl)(3,3-difluoropyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(2-chlorobenzyl)(3,3-difluoroazetidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 1-(5-tert-Butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylazetidinol; (S)(5-tert-Butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidin- 3-ol; (R)-(1-(5-tert-Butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinyl)methanol; -Butyl(2-chlorobenzyl)(3,3,4,4-tetrafluoropyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (R)tert-Butyl(2-chlorobenzyl)(2-(methoxymethyl)pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (2S,3S)(5-tert-Butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) (hydroxymethyl)pyrrolidinol; 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]methylpyrrolidinol -tert-Butylcyclohexylmethyl(3,3-difluoro-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- midine; -tert-Butyl(2,6-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H-[1,2,3]triazolo[4,5- midine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,2,2-trifluoro-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-3,6-difluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-trifluoromethyl-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin ylmethyl]-benzonitrile; -tert-Butyl(3,3-difluoro-pyrrolidinyl)phenethyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -tert-Butyl[(R)(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; and 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] phenyl-ethanol.

The invention relates in particular to a compound of formula (I) ed from -tert-Butyl(3-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,6-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(1-methyl-1H-tetrazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methyl-2H-[1,2,4]triazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; (S)[5-tert-Butyl(4-methyl-furazanylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; [5-tert-Butyl(3-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; (S)[5-tert-Butyl(2-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; (S)[5-tert-Butyl(2-methanesulfonyl-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; (S)[5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; 5-tert-Butyl(4-methyl-furazanylmethyl)(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(3-chloro-pyridinylmethyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -tert-Butyl(2-chloro-benzyl)((R)-2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol; (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol; (S)(5-tert-butyl(2-(trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 3-methylpyrrolidinol; (5-tert-butyl(2-(trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 3-methylpyrrolidinol; (S)(5-tert-butyl(2-(methylsulfonyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- ylpyrrolidinol; and (R)(5-tert-butyl(2-(methylsulfonyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 3-methylpyrrolidinol.

The following compounds of formula (I) are particularly advantageous: (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidin- 3-ol; (S)[5-tert-Butyl(4-methyl-furazanylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin rrolidinol; (S)[5-tert-Butyl(3-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; (S)[5-tert-Butyl(2-methanesulfonyl-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinol; and (S)[5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol.

(S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinol is a particularly ageous compound.

The preparation of compounds of formula (I) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the compounds of the invention are shown in the following schemes. The skills required for carrying out the reactions and purifications of the resulting products are known to those skilled in the art.

The substituents and indices used in the following description of the ses have the significance given herein before unless indicated to the contrary. In more detail, the compounds of formula (I) can be manufactured by the s given below, by the methods given in the examples or by ous methods. Appropriate reaction conditions for the dual reaction steps are known to a person skilled in the art. Also, for reaction conditions described in literature affecting the described reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. . John Wiley & Sons, New York, NY. 1999). We found it convenient to carry out the reactions in the presence or absence of a solvent. There is no ular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. The described reactions can take place over a wide range of temperatures, and the precise on temperature is not critical to the invention. It is convenient to carry out the described reactions in a temperature range between -78 °C to reflux. The time required for the reaction may also vary widely, depending on many s, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 hours to several days will usually suffice to yield the described intermediates and nds. The reaction sequence is not limited to the one yed in the schemes, however, depending on the starting materials and their respective reactivity the sequence of reaction steps can be freely altered. Starting materials are either commercially available or can be prepared by s analogous to the methods given below, by s described in references cited in the description or in the examples, or by methods known in the art.

Scheme 1 R1 A R1 A H R1 a) R1 b) N NH 2 N N A X + A N N N N N N 2 N R II III X=Br or Cl IV R=CONH2, CN R1 A R1 A R1 A H N d) N N e) N N f) N N N N N N N N N N O Cl R2 VI VII I a) Halides II are either commercially available or can be synthesized according to methods known in the art. These s II are conveniently reacted with sodium azide in a suitable solvent such as acetonitrile, ethanol or DMF to afford azide derivatives III.

Alternative preferred conditions involve the use of solvents like DMA, NMP or DMSO, even more preferred are NMP and DMSO. In polar aprotic solvents like NMP and DMSO, the alkylations can usually be conducted at lower temperature than for example in acetonitrile, often at room temperature to 40°C (this is the case for e for BnCl, 1- chloro(chloromethyl)benzene or PMB-Cl ; this depends of course on the vity of the Halides II) and hence provide a better process safety window (caution organic azides are of course know to be potentially ous and process safety has always to be carefully assessed). The addition of water can be cial as it increases the lity of sodium azide and provided more robust kinetic profiles as it helps to dissolves hard clumps of NaN3. It can also lead to a better filterability of the final azide reaction mixture.

Filtration of the reaction mixture might be required for example when the following cycloaddition is performed in a continuous mode in small channels reactors. The azide is not isolated and its solution is best introduced in the next step. This also avoids its ion which can also lead to safety issues. b) Triazole derivatives IV can be prepared by a [3+2] cycloaddition of azide derivatives III with oacetamide in the presence of an appropriate base such as sodium methoxide or sodium ethoxide in a suitable solvent such as methanol, ethanol or DMF. Alternative preferred conditions involve reacting the azide with oacetamide in solvents like NMP or DMSO, in the presence of sodium ide. The batch process is y performed at room temperature to 50°C, preferably between room temperature and 40°C (caution, process safety has always to be carefully ed). The cycloaddition process is also amendable to continuous mode (for a relevant literature example, see Org.

Process Res. Dev., 2009 , 13 (6), pp 406) and in this case the reaction temperature can be increased above 50°C, for example (but not limited to) between 50°C and 90°C, preferably between 60°C and 70°C. c) Triazole derivatives V can be obtained by acylation of IV with an acyl-halide in the presence of a base such as DIEA, DMAP, ne and the like. Double acylation and the formation of nitrile side products have been observed. These can be significant when working for example in pyridine as solvent. However, these can be minimized when using DMA or NMP, preferably DMA as solvent instead of pyridine. Preferred conditions involves the use of 1.0-2 equiv. of pyridine and pivaloyl de, preferably 1.0 to 1.5 equiv, preferably around 1.5 equiv at 50-100°C, preferably between 75-85°C. These high g polar solvents also allow telescoping the following cyclization step which greatly simplifies the process. d) Triazolopyrimidine derivatives VI can be prepared by intramolecular cyclization of triazole derivative V in the presence of a base such as KHCO3, Na2CO 3 and water either with or without a solvent such as methanol, ethanol, e and toluene. Alternative preferred ions involve the use of DMA or NMP as solvents, preferably DMA. The reaction can be performed in the presence of KHCO3 at 130-170°C, preferably between 140 and 160°C. Compound VI may exist as a tautomer or a mixture of tautomers, for example: R1 A H R1 A R1 A N N N N N N N N N N N NH N N N O OH O e) Chlorides VII can be obtained by on of VI with a chlorination reagent such as POCl3, SOCl2 or (COCl)2 in the presence of an appropriate base such as N,N-diethyl aniline, lutidine, or pyridine. Alternative preferred ions involve the use of the Vislmeier reagent as chlorinating agent. It can also be generated in situ by reacting oxalyl chloride with DMF. The chlorination can be performed for example in acetonitrile, DCM or AcOEt, preferably in DCM. These conditions allow for mild reaction temperature and for example, avoid the quench of excess POCl3 upon work-up. The crude t can be introduced in the next step. f) VII are conveniently reacted with various nucleophiles, particularly amines, in the ce of an appropriate base such as triethylamine, DIEA or DBU in a suitable solvent such as acetonitrile, methanol, toluene or DMF to yield triazolo-pyrimidine derivatives I.

If the nucleophile is an alcohol, the reaction can be med using a base such as sodium hydride in a solvent such as DMF preferentially at temperatures between 0 °C and 50 °C or by applying other ions known to a person skilled in the art, to arrive at ethers I.

These derivatives can be the final compounds, however preferably when R1-A = substituted benzyl group such as p-methoxy benzyl, these groups can be cleaved with TFA, CAN, hydrogenation and the like to access derivatives I ( R1-A =H). R1-A = benzyl represents a le alternative ting group. It avoids the use of PMB-Cl (for the preparation of the corresponding azide intermediate III) which is known to have some thermal stability issues (see for example Organic Process Research & pment 2005, 9, 1009-1012) and varying y depending on the supplier. The benzyl group can be cleaved under standard hydrogenolysis conditions also for example in the presence of acids. When HCl is used, the derivatives I (R1-A =H) can potentially be isolated as salts.

The triazole derivatives I (R1-A =H) is conveniently reacted either with a halide (or sulfonate) in the ce of suitable base such as DIEA, DBU, K2CO3, or Cs2CO3 in a solvent such as DMF, dioxane or toluene, or alternatively with an alcohol under Mitsunobu on conditions using suitable diazodicarboxylate (DEAD, DIAD and the like) and phosphine such as PBu3 or PPh3 in an appropriate solvent such as THF, DCM, toluene to afford final triazolo-pyrimidine derivatives I.

The ion also relates to a process for the preparation of a compound of formula (I) comprising one of the following reaction: (a) the reaction of a compound of a (A), a tautomer thereof or a mixture of tautomers thereof, in particular as defined above (A) in the presence of a halogenation reagent and optionally with a base; or (b) the reaction of a compound of formula (B) in the presence of NHR3R4 and optionally with a base; wherein A, R1, R3 and R4 are as defined above.

In step (a), the base is for example N,N-diethyl aniline, lutidine or pyridine.

Halogenation reagents are well known to those skilled in the art. Particular halogenation reagents are nation reagents. Examples of halogenation reagent are POCl3, SOCl2, (COCl)2 or Vilsmeier reagent. POCl3 and the Vilsmeier t are particular halogenation reagents useful in the process of the invention.

In step (b), the base is for e triethylamine, DIEA or DBU.

In step (b), a t can be used, which can be selected for example from acetonitrile, ol, toluene and DMF.

A compound of formula (I) when manufactured according to a process of the ion is also an aspect of the invention.

The invention further relates to a compound of formula (I) for use as therapeutically active substance.

The ion further relates to a pharmaceutical composition comprising a compound of formula (I) and a therapeutically inert carrier.

Also bed herein is the use of a compound of formula (I) for the treatment or prophylaxis of pain, in particular c pain, sclerosis, tion of bone mass, inflammation, ischemia, reperfusion injury, systemic fibrosis, liver is, lung fibrosis, kidney fibrosis, chronic allograft nephropathy, congestive heart failure, myocardial infarction, systemic sclerosis, glomerulonephropathy, thermal injury, burning, hypertrophic scars, s, gingivitis pyrexia, liver cirrhosis or tumors is another object of the invention.

The invention further relates to the use of a compound of formula (I) for the preparation of a medicament for the treatment or prophylaxis of chronic pain, in particular chronic pain, atherosclerosis, regulation of bone mass, inflammation, ia, usion injury, systemic fibrosis, liver fibrosis, lung fibrosis, kidney fibrosis, chronic allograft nephropathy, congestive heart failure, myocardial tion, systemic sclerosis, glomerulonephropathy, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors is a further object of the invention.

The ion also relates to a compound of formula (I) for the treatment or prophylaxis of pain, in particular c pain, atherosclerosis, regulation of bone mass, inflammation, ischemia, reperfusion injury, systemic fibrosis, liver fibrosis, lung fibrosis, kidney fibrosis, chronic allograft nephropathy, congestive heart failure, myocardial infarction, systemic sclerosis, glomerulonephropathy, thermal , burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors.

Also described herein is the use of 3-[(2-chlorophenyl)methyl](1,1- dimethylethyl)(4-morpholinyl)-3H-1,2,3-triazolo[4,5-d]pyrimidine or N-cyclopropyl (1,1-dimethylethyl)(phenylmethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidinamine, in particular 3-[(2-chlorophenyl)methyl](1,1-dimethylethyl)(4-morpholinyl)-3H-1,2,3- triazolo[4,5-d]pyrimidine, for the preparation of a medicament for the treatment or prophylaxis of chronic pain, in particular chronic pain, atherosclerosis, regulation of bone mass, inflammation, ischemia, reperfusion injury, systemic fibrosis, liver fibrosis, lung fibrosis, kidney fibrosis, chronic allograft nephropathy, congestive heart failure, myocardial infarction, ic sclerosis, glomerulonephropathy, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or .

Also described herein is 3-[(2-chlorophenyl)methyl](1,1-dimethylethyl)(4- morpholinyl)-3H-1,2,3-triazolo[4,5-d]pyrimidine or N-cyclopropyl(1,1-dimethylethyl)- 3-(phenylmethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidinamine, in particular 3-[(2- chlorophenyl)methyl](1,1-dimethylethyl)(4-morpholinyl)-3H-1,2,3-triazolo[4,5- d]pyrimidine for the treatment or prophylaxis of pain, in particular chronic pain, atherosclerosis, tion of bone mass, inflammation, ischemia, reperfusion injury, ic fibrosis, liver fibrosis, lung fibrosis, kidney fibrosis, c allograft nephropathy, congestive heart failure, myocardial infarction, systemic sclerosis, glomerulonephropathy, thermal injury, burning, hypertrophic scars, s, gingivitis pyrexia, liver cirrhosis or tumors.

Also bed herein is the use of a nd of formula (I) for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, tion of bone mass, neurodegeneration, stroke, ent ischemic attack or uveitis.

The invention also relates to the use of a compound ing of formula (I) for the preparation of a medicament for the treatment or prophylaxis of pain, atherosclerosis, agerelated macular degeneration, diabetic pathy, glaucoma, diabetes mellitus, inflammation, matory bowel disease, ischemia-reperfusion injury, acute liver failure, liver is, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, ic nephropathy, ulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial tion, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, itis pyrexia, liver cirrhosis or tumors, regulation of bone mass, neurodegeneration, stroke, transient ischemic attack or uveitis.

The ion also relates to a compound of formula (I) for the treatment or prophylaxis of pain, atherosclerosis, lated macular degeneration, diabetic retinopathy, glaucoma, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, ulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, l injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver sis or , regulation of bone mass, neurodegeneration, stroke, transient ischemic attack or uveitis.

Also described herein is a method for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, ic retinopathy, ma, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic aft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, ic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, tion of bone mass, neurodegeneration, , transient ic attack or uveitis, which method comprises administering an effective amount of a compound of a (I) to a patient in need thereof.

The invention particularly relates to a compound of formula (I) for the treatment or prophylaxis of ischemia, reperfusion injury, liver fibrosis or kidney fibrosis, in particular ischemia or reperfusion injury.

The invention is further directed to a compound of formula (I), when manufactured according to a process according to the invention.

Also described herein is a method for the treatment or prophylaxis of pain, in particular chronic pain, atherosclerosis, regulation of bone mass, inflammation, ischemia, reperfusion injury, ic fibrosis, liver fibrosis, lung fibrosis, kidney is, chronic allograft nephropathy, congestive heart failure, myocardial infarction, systemic sclerosis, glomerulonephropathy, l injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, which method comprises administering an effective amount of a compound of formula (I) to a patient in need thereof.

Another embodiment of the invention provides pharmaceutical compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the nds of the invention to prepare such compositions and medicaments. In one e, compounds of formula (I) may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., rs that are non-toxic to recipients at the dosages and trations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8. In one example, a compound of formula (I) is formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of formula (I) are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.

Compositions are ated, dosed, and administered in a fashion consistent with good medical ce. Factors for consideration in this context include the particular disorder being treated, the ular mammal being treated, the al ion of the individual t, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical tioners.

The compounds of the ion may be stered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration.

Parenteral ons e intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.

The nds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking , and further active agents.

A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & s, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, tants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical ition f) or aid in the cturing of the pharmaceutical product (i.e., medicament).

The invention will now be illustrated by the following examples which have no limiting character.

Examples Abbreviations MS = mass spectrometry; CAN = ceric ammonium nitrate; Ac = acetyl; DIEA = N,N- diisopropylethylamine; DBU = 1,8-Diazabicyclo[5.4.0]undecene; DMF = dimethylformamide; HPLC = LC = high mance liquid chromatography; THF = tetrahydrofurane; TFA = trifluoroacetic acid; Ph = ; DCM = dichloromethane.

BnN3 = benzyl azide; CSTR = continuous strirred tank reactor.

Chiral separation of 1-(3-Benzyltert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methyl-pyrrolidinol (example 221, step a) yielded the respective enantiopure R and S derivatives. However, the vocal stereochemical assignment is pending. Therefore, the stereochemical assignment for enantiopure examples 221-230 has not been made.

Example 1 ence example) -Butyl(2-chloro-benzyl)morpholinyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N O a) 5-Amino(2-chlorobenzyl)-1H-1,2,3-triazolecarboxamide N NH2 N 2 A mixture of 1-(bromomethyl)chlorobenzene (5 g, 24.3 mmol) and sodium azide (2.37 g, 36.5 mmol) in acetonitrile (48.7 mL) was refluxed for 3 h under N2 atmosphere. Then, the mixture was filtered and concentrated in vacuo. The residue was diluted in DCM, washed with H2O and brine, dried over Na2SO4 and concentrated in vacuo to afford crude 1-(azidomethyl)chlorobenzene. The residue was used for the next on without further cation.

A mixture of the above crude residue, 2-cyanoacetamide (1.82 g, 21.7 mmol) and sodium ethanolate (1.47 g, 21.7 mmol) in ethanol (43.3 mL) was ed for 3 h under N2 atmosphere. The mixture was concentrated in vacuo, diluted with 4M AcOH aq. and filtered. The residue was washed with H2O and dried in vacuo to afford 5-amino(2- chlorobenzyl)-1H-1,2,3-triazolecarboxamide as pale-orange solid (5.10 g, 94% for 2 steps). MS(m/e): 252.1 (MH+). b) 5-tert-Butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)-one N N O A mixture of 5-amino(2-chlorobenzyl)-1H-1,2,3-triazolecarboxamide (2 g, 7.95 mmol) and pivaloyl chloride (1.47 mL, 11.9 mmol) in pyridine (3.98 mL) was stirred at 80 °C for 2 h under N2 atmosphere. Then, to the reaction e was added 8M sodium hydroxide aq. (2.98 mL, 23.8 mmol) and methanol (3.98 mL). After being stirred at 80 °C for 2 h, the reaction mixture was poured into 1M HCl aq., ted with diethyl ether, washed with 2M HCl, water and brine, dried over Na2SO4 and concentrated in vacuo to afford the mixture of crude 1-(2-chlorobenzyl)pivalamido-1H-1,2,3-triazole carboxamide and N-(1-(2-chlorobenzyl)cyano-1H-1,2,3-triazolyl)pivalamide. The residue was used for the next reaction without further purification.

A mixture of the above crude residue and KHCO3 (3.00 g, 30.0 mmol) in H2O (60.0 mL) was ed for 18 h. The reaction mixture was poured into 1M HCl aq., extracted with EtOAc, washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude residue was purified by flash chromatography (silica gel, 10% to 70% EtOAc in heptane) to afford 5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)-one as white solid (1.03 g, 41% for 2 steps). MS(m/e): 318.2 (MH+). c) 5-tert-Butyl(2-chloro-benzyl)morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine A mixture of 5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)- one (12.3 mg, 38.7 µmol) and N,N-diethylaniline (12.3 µL, 77.4 µmol) in POCl3 (250 µL, 2.73 mmol) was refluxed for 3 h under N2 atmosphere. The reaction mixture was concentrated in vacuo, diluted with EtOAc, washed with cold H2O and brine, dried over Na2SO4 and concentrated in vacuo to afford crude 5-tert-butylchloro(2- chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine. The residue was used for the next reaction without further purification.

A mixture of the above crude residue, morpholine (6.77 µL, 77.4 µmol) and DIEA (13.5 µL, 77.4 µmol) in acetonitrile (200 µL) was stirred at the room temperature overnight. The on mixture was directly ed by preparative HPLC (column: Gemini 5um C18 110A 75 x 30mm. mobile phase: water (0.05% Et3N): acetonitrile 50:50% to 5:95%. WL: 254 nm Flow: 30 mL/min.) to afford the title compound as yellow solid (5.8 mg, 39% for 2 steps). MS(m/e): 387.3 (MH+).

Example 2 5-tert-Butyl(2-chloro-benzyl)piperidinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and dine and isolated as light-yellow solid (10.0 mg, 55%). MS(m/e): 385.4 (MH+).

Example 3 -tert-Butyl(2-chloro-benzyl)(4,4-difluoro-piperidinyl)-3H-[1,2,3]triazolo[4,5- d] pyrimidine N N F F In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 4,4-difluoropiperidine hydrochloride and isolated as light-yellow gum (10.9 mg, 55%). MS(m/e): 421.4 (MH+).

Example 4 -tert-Butyl(2-chloro-benzyl)(4-methyl-piperazinyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine N N In analogy to the ure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 1-methylpiperazine and isolated as light-yellow solid (13.4 mg, 71%). MS(m/e): 400.4 (MH+). -tert-Butyl(2-chloro-benzyl)pyrrolidinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of -butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and pyrrolidine and isolated as white solid (12.4 mg, 71%). MS(m/e): 371.4 (MH+).

Example 6 -tert-Butyl(2-chloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N F In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3,3-difluoropyrrolidine hydrochloride and isolated as colorless gum (13.3 mg, 69%). ): 407.4 (MH+).

Example 7 [5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-ethylamine N N In analogy to the procedure described for the sis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and ethanamine hydrochloride and isolated as white solid (1.1 mg, 7%). MS(m/e): 345.3 (MH+).

Example 8 [5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-cyclohexylamine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was ed from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and cyclohexane-amine and isolated as light-yellow solid (3.8 mg, 20%). MS(m/e): 399.4 (MH+).

Example 9 [5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-diethylamine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and diethylamine and ed as ess gum (11.5 mg, 65%). MS(m/e): 373.4 (MH+).

Example 10 -tert-Butyl(2-chloro-benzyl)(2-oxaaza-spiro[3.3]heptyl)-3H-[1,2,3]triazolo [4,5-d]pyrimidine N N O In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 2-oxaazaspiro[3.3]heptane oxalate and isolated as white solid (10.8 mg, 57%). MS(m/e): 399.4 (MH+).

Example 11 7-Azetidinyltert-butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the sis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and azetidine and isolated as white solid (9.8 mg, 52%).

MS(m/e): 357.3 (MH+).

Example 12 -Butyl(2-chloro-benzyl)(3,3-difluoro-azetidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N F F In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3,3-difluoroazetidine hydrochloride and isolated as light-yellow gum (11.9 mg, 64%). MS(m/e): 393.4 (MH+).

Example 13 ert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]methylazetidinol N N In analogy to the procedure bed for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and inol hydrochloride and ed as lightyellow solid (8.0 mg, 46%). MS(m/e): 373.4 (MH+).

Example 14 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]methyl- azetidinol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- holinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was ed from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and azetidinol hydrochloride and isolated as white solid (10.3 mg, 56%). MS(m/e): 387.4 (MH+).

Example 15 -tert-Butyl(2-chloro-benzyl)(3-methoxy-azetidinyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3-methoxyazetidine hydrochloride and isolated as white solid (11.0 mg, 60%). MS(m/e): 387.4 (MH+).

Example 16 -tert-Butyl(2-chloro-benzyl)((2R,6S)-2,6-dimethyl-morpholinyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (2S,6R)-2,6-dimethylmorpholine and isolated as white solid (13.1 mg, 67%). MS(m/e): 415.5 (MH+).

Example 17 -tert-Butyl(2-chloro-benzyl)(3-methyl-morpholinyl)-3H-[1,2,3]triazolo[4,5- d] pyrimidine N N In analogy to the ure described for the synthesis of -butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was ed from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3-methylmorpholine and isolated as light-yellow gum (12.7 mg, 67%). MS(m/e): 401.5 (MH+).

Example 18 {4-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- morpholinyl}-methanol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and morpholinylmethanol and isolated as light-yellow gum (11.8 mg, 60%). MS(m/e): 417.5 (MH+).

Example 19 -tert-Butyl(2-chloro-benzyl)thiazolidinyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N S In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and thiazolidine and isolated as yellow gum (10.6 mg, 58%). MS(m/e): 389.4 (MH+).

Example 20 -Butyl(2-chloro-benzyl)thiomorpholinyl-3H-[1,2,3]triazolo[4,5-d] pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and thiomorpholine and isolated as light-yellow gum (10.2 mg, 54%). MS(m/e): 403.4 (MH+). e 21 -tert-Butyl(2-chloro-benzyl)(1,1-dioxo-1λ6-thiomorpholinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine N N O O In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title nd was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and thiomorpholine 1,1-dioxide and isolated as white solid (13.5 mg, 66%). MS(m/e): 435.4 (MH+).

Example 22 -tert-Butyl(2-chloro-benzyl)[1,4]oxazepanyl-3H-[1,2,3]triazolo[4,5-d] pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 1,4-oxazepane hydrochloride and isolated as white gum (12.0 mg, 63%). MS(m/e): 401.5 (MH+).

Example 23 -tert-Butyl(2-chloro-benzyl)(2,2-dimethyl-morpholinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N O In y to the procedure described for the sis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 2,2-dimethylmorpholine and isolated as ess gum (13.7 mg, 70%). MS(m/e): 415.4 (MH+).

Example 24 -tert-Butyl(2-chloro-benzyl)(3,3-dimethyl-morpholinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the ure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3,3-dimethylmorpholine and isolated as ess gum (12.5 mg, 64%). MS(m/e): 415.4 (MH+).

Example 25 -tert-Butyl(2-chloro-benzyl)((2R,5R)-2,5-dimethyl-pyrrolidinyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was ed from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (2R,5R)-2,5-dimethylpyrrolidine and isolated as colorless gum (11.2 mg, 60%). MS(m/e): 399.4 (MH+).

Example 26 (S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (S)-pyrrolidinol and isolated as colorless gum (12.5 mg, 69%). MS(m/e): 387.3 (MH+). ative conditions: Step 1: 5-amino[(2-chlorophenyl)methyl]triazolecarboxamide N 2 N NH Sodium azide (3.36 g, 51.1 mmol, Eq: 1.05) was charged in the reactor followed by DMSO (35.2 g, 32.0 ml) and Hunig's base (642 mg, 868 µl, 4.87 mmol, Eq: 0.1). The suspension was stirred for 10 Min. at 25°C. Then 1-chloro(chloromethyl)benzene (8 g, 6.29 ml, 48.7 mmol, Eq: 1.00) was added dropwise over 60 min.(Tr = 25°C) and stirred at °C until reaction completion (< 2h ). The resulting white suspension was d with water (1.6 g, 1.6 ml) and stirred for 45 Min. at R.T. The suspension was filtered and the filter cake was washed with DMSO (17.6 g, 16.0 ml) to give a colorless on of 1- (azidomethyl)chloro-benzene solution.

In a te reactor, DMSO (17.6 g, 16.0 ml) was charged followed by 32% aqueous NaOH (6.09 g, 4.51 ml, 48.7 mmol, Eq: 1.0) and water (5.00 g, 5.00 ml). A solution consisting of 2-cyanoacetamide (6.2 g, 73.0 mmol, Eq: 1.50) and DMSO (17.6 g, 16.0 ml) was added dropwise over 15 min. at 25°C.

The previsouly prepared azide solution was added dropwise at 25°C within 4h. After an additional 15h reaction, water (120 g, 120 ml) was added dropwise over 10 min (exothermic). The resulting sion was cooled to 0°C. After 1h30 at 0°C the suspension was filtered. The filter cake was washed with water (40.0 g, 40.0 ml) and dried under reduced re 50°C/5 mbar until constant weight to give 10.87 g of the title compound as a white powder. MS(m/e): 251.9 (MH+).

Step 2: 5-tert-butyl[(2-chlorophenyl)methyl]-4H-triazolo[4,5-d]pyrimidinone Cl Cl Cl N NH N NH 2 N N N N N N NH N NH 2 2 N O O O -amino(2-chlorobenzyl)-1H-1,2,3-triazolecarboxamide (10.80 g, 42.9 mmol, Eq: 1.00) was suspended in N,N-dimethylacetamide (50.2 g, 54.0 ml). Pyridine (5.1 g, 5.19 ml, 64.4 mmol, Eq: 1.5) was added followed by pivaloyl chloride (7.84 g, 8.00 ml, 64.4 mmol, Eq: 1.5) and the reaction mixture was heated to ca 80°C. After 3h reaction (and complete conversion of the starting material to the intermediate), KHCO3 (21.6 g, 215 mmol, Eq: .00) was added and the suspension was heated to Tj = 155°C for 24h to convert the 1-[(2- phenyl)methyl](2,2-dimethylpropanoylamino)triazolecarboxamide intermediate to the product. The reaction e was cooled to RT and water (254 g, 254 ml) was added dropwise over 30 min. The brown suspension was cooled to 0°C, d for 1h30 min and was filtered. The filter cake was washed with water (43.2 g, 43.2 ml) and dried at 50°C/5 mbar to give 11g of the title compound as an off-white powder. MS(m/e): 318.0 (MH+).

Step 3: 5-tert-butylchloro[(2-chlorophenyl)methyl]triazolo[4,5-d]pyrimidine N N DMF (10.1 g, 10.7 ml, 139 mmol, Eq: 4.14) and rmethane (113 g, 85.6 ml) were charged in the reactor and the solution was heated to 35°C. Oxalylchloride (8.66 g, 5.86 ml, 66.9 mmol, Eq: 2) was added over 1h at 35°C. After 45 min at 35°C, a light turbid solution of 5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)-one (10.7 g, 33.4 mmol, Eq: 1.00) in Dichlormethane (32 ml) and DMF (2 ml) was added over 15min at 35°C.

After 4h at 35°C, the reaction mixture was cooled to RT and was slowly added onto cold (0-5°C) half saturated aqueous NaHCO3 (160 ml). The organic phase was separated and washed with water (119 g, 119 ml) and half saturated aqueous NaCl (119 ml). The organic phase was dried over MgSO4, rotavaped and dried at 50°C/10 mbar to give 10.89g of the title compound as an oil which solidifies on standing to provide a light yellow solid. ): 335.9 (MH+).

Step 4 (3S)[5-tert-butyl[(2-chlorophenyl)methyl]triazolo[4,5-d]pyrimidin yl]pyrrolidinol 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine (10 g, 29.7 mmol, Eq: 1.00) was dissolved in Acetonitrile (54.6 g, 70.0 ml). N-Ethyldiisopropylamin (7.84 g, 10.3 ml, 59.5 mmol, Eq: 2) was added dropwise over 5-10 min. After 10 min at RT, a solution of (S)-pyrrolidinol (2.94 g, 2.8 ml, 32.7 mmol, Eq: 1.1) in Acetonitrile (2.27 g, 2.91 ml) added dropwise over 30 min at 20°C. After 2h30 reaction, toluene (86.5 g, 100 ml) was added and the on e was concentrated under reduced pressure to remove most of the acetonitrile. A 10% aqueous citric acid solution (100 ml) was added.

The aqueous phase was separated and extracted with toluene (86.5 g, 100 ml). The organic phases were washed sequentially with half saturated aqueous NaHCO3 (50 ml) and half saturated aqueous NaCl (50 ml). The organic phases were ed dried over MgSO4 and rotavaped at 0 mbar. The crude product was taken up in ethanol (150ml) and concentrated under d pressure. This was repeated twice in order to remove toluene and gave 11.1 g of the crude title compound as a light yellow solid/foam.

The product can be crystallized, for example, from toluene/heptane or acetone/water.

Crystallization from Toluene / n-Heptane 1.0 g of the crude product was dissolved at room temperature in 4 ml of Toluene. Then 8 ml of ane was added in one portion. The clear, light yellow solution was seeded (the seed ls were obtained from a test tube crystallization in Toluene / n-heptane). The crystallization started slowly. After 1h at R.T., the white suspension was filtered. The filter cake was washed with n-Heptane and dried under reduced pressure (5-10 mbar) at 50°C overnight then at 80°C for 8h to give 0.9 g of the title compound.

Crystallization from Acetone / Water .5 g of the crude product was dissolved at room temperature in 30 ml of Acetone. Then 13.6 ml of water was added in one portion. The clear, light yellow solution was seeded (the seed crystals were obtained from a test tube crystallization in e / water). The crystallization started slowly. After stirring overnight at RT, the white suspension was cooled down to 0°C, stirred for 2h at 0°C and filtered. The filter cake was washed with cold acetone/water 1:1 and dried at 80°C under reduced pressure to give 4.9 g of the title compound.

Example 27 (R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinol N N In analogy to the procedure described for the synthesis of -butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and rrolidinol and isolated as colorless gum (11.6 mg, 64%). MS(m/e): 387.3 (MH+).

Example 28 -tert-Butyl(2-chloro-benzyl)(3-methoxy-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d] pyrimidine N N In y to the procedure bed for the synthesis of 5-tert-butyl(2-chloro-benzyl)- holinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3-methoxypyrrolidine hydrochloride and isolated as colorless gum (13.2 mg, 70%). MS(m/e): 401.4 (MH+).

Example 29 5-tert-Butyl(2-chloro-benzyl)(2,2-dimethyl-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 2-methylpyrrolidine and isolated as white solid (13.2 mg, 70%). MS(m/e): 399.4 (MH+).

Example 30 -tert-Butyl(2-chloro-benzyl)(2-methyl-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d] pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 2-methylpyrrolidine and isolated as white solid (13.0 mg, 70%). MS(m/e): 385.4 (MH+).

Example 31 -tert-Butyl(2-chloro-benzyl)(2-oxaaza-spiro[3.4]octyl)-3H-[1,2,3]triazolo [4,5-d]pyrimidine N N O In analogy to the procedure described for the sis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 2-oxaazaspiro[3.4]octane oxalate and isolated as ess gum (2.6 mg, 13%). MS(m/e): 413.4 (MH+).

Example 32 ert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- piperidinol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was ed from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and piperidinol and isolated as light-yellow gum (12.6 mg, 67%). MS(m/e): 401.4 (MH+).

Example 33 (S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- piperidinol N N OH In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (S)-piperidinol hydrochloride and ed as light-yellow gum (13.3 mg, 70%). MS(m/e): 401.4 (MH+).

Example 34 (R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- piperidinol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (R)-piperidinol hydrochloride and isolated as ess gum (8.3 mg, 44%). MS(m/e): 401.4 (MH+).

Example 35 -tert-Butyl(2-chloro-benzyl)(6-oxaaza-spiro[3.3]heptyl)-3H-[1,2,3]triazolo ]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 6-oxaazaspiro[3.3]heptane oxalate and isolated as yellow gum (12.5 mg, 65%). MS(m/e): 399.4 (MH+).

Example 36 -tert-Butyl(2-chloro-benzyl)((S)fluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine N N In y to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] dine and (S)fluoropyrrolidine hydrochloride and isolated as light-yellow solid (16.5 mg, 90%). MS(m/e): 389.4 (MH+).

Example 37 {(R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-methanol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (R)-pyrrolidinylmethanol and isolated as light- yellow gum (14.2 mg, 75%). MS(m/e): 401.4 (MH+). e 38 {(S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-methanol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (S)-pyrrolidinylmethanol and isolated as ellow gum (14.6 mg, 77%). MS(m/e): 401.4 (MH+).

Example 39 -tert-Butyl(2-chloro-benzyl)[1,2]oxazinanyl-3H-[1,2,3]triazolo[4,5-d] pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- ]triazolo[4,5-d] pyrimidine and [1,2]oxazinane and isolated as light-yellow gum (13.6 mg, 75%). MS(m/e): 387.4 (MH+).

Example 40 -tert-Butyl(2-chloro-benzyl)isoxazolidinyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and isoxazolidine hydrochloride and isolated as white solid (13.1 mg, 74%). MS(m/e): 373.4 (MH+).

Example 41 7-Aziridinyltert-butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and aziridine and isolated as white solid (4.9 mg, 30%). ): 343.3 (MH+).

Example 42 -Butyl(2-chloro-benzyl)((R)fluoro-pyrrolidinyl)-3H- ]triazolo[4,5-d] pyrimidine N N In analogy to the procedure bed for the synthesis of 5-tert-butyl(2-chloro-benzyl)- holinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (R)fluoropyrrolidine hydrochloride and isolated as light-yellow gum (9.8 mg, 54%). MS(m/e): 389.4 (MH+).

Example 43 -tert-Butyl(2-chloro-benzyl)(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine N N F F F F In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 1, step c), the title compound was ed from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3,3,4,4-tetrafluoropyrrolidine hydrochloride and isolated as light-yellow gum (12.6 mg, 60%). MS(m/e): 443.4 (MH+).

Example 44 -tert-Butyl(2-chloro-benzyl)((R)methoxymethyl-pyrrolidinyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- ]triazolo[4,5-d] pyrimidine and (R)(methoxymethyl)pyrrolidine and isolated as colorless gum (12.4 mg, 64%). MS(m/e): 415.4 (MH+).

Example 45 -tert-Butyl(2-chloro-benzyl)((S)methoxymethyl-pyrrolidinyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title nd was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (S)(methoxymethyl)pyrrolidine and isolated as light-yellow gum (12.0 mg, 61%). MS(m/e): 415.4 (MH+).

Example 46 (2S,4S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl] -pyrrolidinecarbonitrile N N N N F In analogy to the procedure described for the sis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (2S,4S)fluoropyrrolidinecarbonitrile and isolated as light-yellow gum (10.6 mg, 54%). MS(m/e): 414.4 (MH+).

Example 47 -Butyl(2-chloro-benzyl)(1,1-dioxo-1λ6-isothiazolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine N N N O A mixture of 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine (15.9 mg, 47.2 µmol), 1,1-dioxo-isothiazolidine (11.4 mg, 94.4 µmol) and DBU (14.2 µL, 94.4 µmol) in DMF (250 µL) was stirred at the room temperature overnight. The reaction mixture was directly purified by preparative HPLC (column: Gemini 5um C18 110A 75 x 30mm. mobile phase: water (0.05% Et3N): acetonitrile 75:25% to 5:95%. WL: 230 nm Flow: 30 mL/min.) to afford the title compound as white solid (3.10 mg, 16%). MS(m/e): 387.3 (MH+).

Example 48 {4-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- morpholinyl}-methanol N N In analogy to the ure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and morpholinylmethanol and isolated as light-yellow gum (13.3 mg, 68%). ): 417.4 (MH+).

Example 49 (R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinecarbonitrile N N N N In analogy to the procedure described for the sis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (R)-pyrrolidinecarbonitrile hydrochloride and ed as light-yellow solid (9.7 mg, 52%). MS(m/e): 396.4 (MH+).

Example 50 (S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinecarbonitrile N N N N In analogy to the ure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (S)-pyrrolidinecarbonitrile hydrochloride and isolated as light-yellow solid (11.5 mg, 65%). MS(m/e): 396.4 (MH+).

Example 51 (2S,3S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl] hydroxymethyl-pyrrolidinol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] dine and (2S,3S)(hydroxymethyl)pyrrolidinol and isolated as light-yellow gum (10.3 mg, 52%). MS(m/e): 417.4 (MH+).

Example 52 (2S,3R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- 2-hydroxymethyl-pyrrolidinol N N OH In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (2S,3R)(hydroxymethyl)pyrrolidinol and isolated as yellow gum (9.6 mg, 49%). MS(m/e): 417.4 (MH+).

Example 53 -tert-Butyl(2-chloro-benzyl)(2-oxaaza-spiro[3.4]octyl)-3H-[1,2,3]triazolo [4,5-d]pyrimidine N N N O In analogy to the procedure described for the sis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 5-azaspiro[3.4]octane oxalate and isolated as white solid (8.4 mg, 43%). MS(m/e): 413.4 (MH+).

Example 54 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]methylpyrrolidinol N N N N In analogy to the procedure described for the sis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3-methylpyrrolidinol hydrochloride and isolated as white solid (14.1 mg, 75%). MS(m/e): 401.4 (MH+).

Example 55 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidine-3,4-trans-diol N N OH OH In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and pyrrolidine-3,4-trans-diol and isolated as white solid (9.1 mg, 48%). MS(m/e): 403.4 (MH+).

Example 56 (3S,4R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- idine-3,4-diol N N OH OH In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chloro-benzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (3R,4S)-pyrrolidine-3,4-diol and isolated as light- yellow gum (10.3 mg, 54%). MS(m/e): 403.4 (MH+).

Example 57 -tert-Butyl(4-methoxy-benzyl)morpholinyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N a) 5-Amino(4-methoxybenzyl)-1H-1,2,3-triazolecarboxamide N NH2 A mixture of 1-(chloromethyl)methoxybenzene (20 g, 128 mmol) and sodium azide (12.5 g, 192 mmol) in acetonitrile (255 mL) was refluxed for 5 h under N2 atmosphere.

The mixture was filtered and concentrated in vacuo. The residue was diluted with DCM, washed with H2O and brine, dried over Na2SO4 and concentrated in vacuo to afford crude 1-(azidomethyl)methoxybenzene. The residue was used for the next reaction t further purification.

A mixture of the above crude residue, 2-cyanoacetamide (10.8 g, 128 mmol) and sodium ethanolate (8.71 g, 128 mmol) in ethanol (256 mL) was refluxed for 21 h under N2 atmosphere. The mixture was concentrated in vacuo, diluted with 4M AcOH aq. and filtered. The residue was washed with H2O and dried in vacuo to afford 5-amino(4- methoxybenzyl)-1H-1,2,3-triazolecarboxamide as pale-orange solid (26.5 g, 84% for 2 steps). ): 248.1 (MH+). b) 5-tert-Butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)-one N N A mixture of 5-amino(4-methoxybenzyl)-1H-1,2,3-triazolecarboxamide (10.0 g, 40.4 mmol) and pivaloyl chloride (7.47 mL, 60.7 mmol) in pyridine (20.2 mL) was stirred at 80 °C for 2 h under N2 here. Then, to the on mixture was added 8 M sodium hydroxide aq. (15.2 mL, 121 mmol) and methanol (20.2 mL). After being stirred at 80 °C for 1 h, the reaction e was poured into 1M HCl aq., extracted with diethyl ether, washed with 2M HCl aq., water and brine, dried over Na 2SO 4 and concentrated in vacuo to afford the mixture of crude 1-(4-methoxybenzyl)pivalamido-1H-1,2,3-triazole amide and N-(4-cyano(4-methoxybenzyl)-1H-1,2,3-triazolyl)pivalamide. The residue was used for the next reaction without further cation.

A mixture of the above crude residue and KHCO3 (12.1 g, 121 mmol) in H2O (242 mL) was refluxed for 18 h. The reaction mixture was poured into 1M HCl aq., extracted with EtOAc, washed with brine, dried over Na2SO 4 and concentrated in vacuo. The crude residue was purified by flash chromatography (silica gel, 10% to 70% EtOAc in heptane) to afford 5-tert-butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)-one (4.44 g, 35% for 2 steps). MS(m/e): 314.2 (MH+). c) 4-(5-tert-Butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)morpholine A mixture of 5-tert-butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)- one (50.0 mg, 160 µmol) and N,N -diethylaniline (50.8 µL, 319 µmol) in POCl3 (1000 µL, .9 mmol) was refluxed for 4 h under N2 atmosphere. The reaction e was concentrated in vacuo, diluted with EtOAc, washed with cold H2O and brine, dried over Na 2SO 4 and concentrated in vacuo to afford crude 5-tert-butylchloro(4- methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine. The residue was used for the next reaction without r purification.

A mixture of the above crude residue, morpholine (28.0 µL, 320 µmol) and DIEA (55.9 µL, 320 µmol) in itrile (250 µL) was stirred at the room temperature overnight. The reaction mixture was directly purified by ative HPLC (column: Gemini 5um C18 110A 75 x 30mm. mobile phase: water (0.05% Et3N): acetonitrile 45:55% to 5:95%. WL: 280 nm Flow: 30 mL/min.) to afford the title compound as white solid (47.7 mg, 78% for 2 steps). MS(m/e): 383.4 (MH+).

Example 58 -tert-Butylmorpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N A mixture of 4-(5-tert-butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)morpholine (10.0 mg, 26.1 µmol) and TFA (250 µL) was refluxed for 5 h under N2 atmosphere. Then, the reaction e was trated in vacuo and purified by preparative HPLC (column: Gemini 5um C18 110A 75 x 30mm. mobile phase: water (0.05% Et3N): acetonitrile 85:15% to 5:95%. WL: 300 nm Flow: 30 mL/min.) to afford the title compound as white solid (0.9 mg, 13%). MS(m/e): 263.3 (MH+).

Example 59 -Butyl(2-chlorofluoro-benzyl)morpholinyl-3H-[1,2,3]triazolo[4,5- midine N N A mixture of 4-(5-tert-butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)morpholine (49.0 mg, 128 µmol) and TFA (1000 µL) was refluxed for 8 h under N2 atmosphere. The reaction mixture was concentrated in vacuo to afford crude to 5-tert- butylmorpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine. The residue was used for the next reaction t further purification.

A mixture of the portion of above residue (42.0 µmol), and 1-(bromomethyl)chloro fluorobenzene (18.8 mg, 84.0 µmol) and DBU (12.7 µL, 84.0 µmol) in DMF (250 µL) was stirred at the room temperature overnight. The reaction mixture was directly purified by preparative HPLC (column: Gemini 5um C18 110A 75 x 30mm. mobile phase: water (0.05% Et3N): acetonitrile 70:30% to 5:95%. WL: 300 nm Flow: 30 mL/min.) to afford the title compound as light-yellow solid (8.3 mg, 49%). MS(m/e): 405.4 (MH+).

Example 60 -Butyl(3,3-difluoro-pyrrolidinyl)(4-methoxy-benzyl)-3H-[1,2,3]triazolo [4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 4-(5-tert-butyl(4-methoxy benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholine (example 58, step c), the title compound was prepared from 5-tert-butylchloro(4-methoxybenzyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and fluoropyrrolidine hydrochloride and isolated as white solid (271 mg, 83%). MS(m/e): 403.4 (MH+).

Example 61 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N A mixture of 5-tert-butyl(3,3-difluoro-pyrrolidinyl)(4-methoxy-benzyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine (264 mg, 656 µmol) and TFA (5.0 mL) was refluxed for 8 h under N2 atmosphere. The reaction mixture was concentrated in vacuo to afford crude to 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine. The residue was used for the next on without further purification.

A mixture of the portion of above e (41.0 µmol), and iodoethane (6.63 µL, 82.0 µmol) and DBU (12.4 µL, 82.0 µmol) in DMF (250 µL) was stirred at the room temperature overnight. The reaction mixture was directly purified by preparative HPLC (column: Gemini 5um C18 110A 75 x 30mm. mobile phase: water (0.05% Et3N): acetonitrile 60:40% to 5:95%. WL: 300 nm Flow: 30 mL/min.) to afford the title compound as light-yellow gum (0.6 mg, 4%). MS(m/e): 311.3 (MH+).

Example 62 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methoxy-ethyl)-3H- [1,2,3]triazolo[4,5-d] dine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-bromomethoxyethane and ed as lightyellow gum (2.5 mg, 18%). MS(m/e): 341.3 (MH+).

Example 63 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl]- N N F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-bromoethanol and isolated as white solid (5.8 mg, 43%). ): 327.3 (MH+).

Example 64 -tert-Butylcyclohexylmethyl(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine N N In analogy to the procedure described for the sis of 5-tert-butyl(3,3-difluoro- pyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo ]pyrimidine and (bromomethyl)cyclohexane and isolated as white solid (4.2 mg, 27%). MS(m/e): 379.5 (MH+).

Example 65 5-tert-Butyl(3-chloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- ]triazolo [4,5-d]pyrimidine and 1-(bromomethyl)chlorobenzene and isolated as light-yellow gum (7.0 mg, 42%). MS(m/e): 407.4 (MH+).

Example 66 -tert-Butyl(4-chloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- ]triazolo[4,5-d] pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl hyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(bromomethyl)chlorobenzene and isolated as white solid (5.8 mg, 35%). MS(m/e): 407.4 (MH+). e 67 -tert-Butyl(2,3-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine N N F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(bromomethyl)-2,3-dichlorobenzene and isolated as colorless gum (6.7 mg, 37%). ): 441.3 (MH+).

Example 68 -tert-Butyl(2,4-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(bromomethyl)-2,4-dichlorobenzene and isolated as colorless gum (6.5 mg, 36%). MS(m/e): 441.3 (MH+).

Example 69 -tert-Butyl(2,5-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- ]triazolo [4,5-d]pyrimidine Cl N F In analogy to the procedure described for the synthesis of -butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)-1,4-dichlorobenzene and isolated as white solid (6.6 mg, 37%). MS(m/e): 441.4 (MH+).

Example 70 -tert-Butyl(2,6-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)-1,3-dichlorobenzene and isolated as white solid (5.2 mg, 29%). MS(m/e): 441.3 (MH+).

Example 71 -tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine N N F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl hyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- ]triazolo [4,5-d]pyrimidine and 1-(bromomethyl)chlorofluorobenzene and isolated as colorless gum (5.8 mg, 33%). MS(m/e): 425.4 (MH+).

Example 72 -tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was prepared from -butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-chloro(chloromethyl)fluorobenzene and isolated as white solid (6.8 mg, 39%). MS(m/e): 425.4 (MH+).

Example 73 -Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H-[1,2,3]triazolo [4,5-d]pyrimidine N N F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)pyridine hydrobromide and isolated as light-yellow solid (4.2 mg, 27%). MS(m/e): 374.4 (MH+).

Example 74 -tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H-[1,2,3]triazolo [4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from -butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-(chloromethyl)pyridine hydrochloride and isolated as light-yellow gum (2.5 mg, 16%). MS(m/e): 374.4 (MH+).

Example 75 -tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H-[1,2,3]triazolo [4,5-d]pyrimidine N N F In analogy to the procedure described for the sis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 4-(bromomethyl)pyridine hydrobromide and isolated as orange solid (5.4 mg, 35%). MS(m/e): 374.4 (MH+). e 76 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,2,2-trifluoro-ethyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine N N In y to the procedure bed for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl hyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2,2,2-trifluoroethyl trifluoromethanesulfonate and isolated as light-yellow gum (0.9 mg, 6%). MS(m/e): 365.3 (MH+).

Example 77 -tert-Butyl(2-chloro-4,5-difluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3] triazolo[4,5-d]pyrimidine F N F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(bromomethyl)chloro-4,5-difluorobenzene and isolated as colorless gum (8.3 mg, 45%). ): 443.4 (MH+).

Example 78 -tert-Butyl(2-chloro-3,6-difluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3] triazolo[4,5-d]pyrimidine N N F N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl hyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)chloro-1,4-difluorobenzene and isolated as white solid (8.0 mg, 44%). ): 443.4 (MH+).

Example 79 3-(2-Bromo-benzyl)tert-butyl(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine N N F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-bromo(bromomethyl)benzene and isolated as ess gum (6.6 mg, 35%). MS(m/e): 451.3 (MH+).

Example 80 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-trifluoromethyl-benzyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine F F N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and momethyl)(trifluoromethyl)benzene and isolated as light-yellow gum (7.8 mg, 43%). MS(m/e): 441.4 (MH+).

Example 81 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methoxy-benzyl)-3H-[1,2,3]triazolo [4,5-d]pyrimidine N N F In analogy to the ure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(chloromethyl)methoxybenzene and isolated as light-yellow gum (5.7 mg, 34%). MS(m/e): 403.4 (MH+).

Example 82 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-trifluoromethoxy-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl hyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and momethyl)(trifluoromethoxy)benzene and isolated as light-yellow gum (7.3 mg, 39%). MS(m/e): 457.4 (MH+).

Example 83 ert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin ylmethyl]-benzonitrile N N F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)benzonitrile and isolated as white solid (6.8 mg, 41%). MS(m/e): 398.3 (MH+).

Example 84 -tert-Butyl(3,3-difluoro-pyrrolidinyl)phenethyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and (2-bromoethyl)benzene and isolated as light-yellow gum (4.8 mg, 30%). MS(m/e): 387.4 (MH+).

Example 85 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl]- yl-ethanone N N F In analogy to the procedure described for the sis of 5-tert-butyl(3,3-difluoropyrrolidinyl )ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was ed from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-bromophenylethanone and isolated as light- green solid (9.5 mg, 55%). MS(m/e): 401.4 (MH+).

Example 86 -tert-Butyl[(R)(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N To a solution of 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine (41.3 µmol), (S)(2-chlorophenyl)ethanol (12.9 mg, 82.6 µmol) and PPh3 (21.7 mg, 82.6 µmol) in THF(250 µL) was added DEAD (13.1 µL, 82.6 µmol) at 0 °C.

After being stirred at the room temperature for 2 h, the on mixture was directly purified by preparative HPLC (column: Gemini 5um C18 110A 75 x 30mm. mobile phase: water (0.05% Et3N): acetonitrile 50:50% to 5:95%. WL: 300 nm Flow: 30 mL/min.) to afford the title compound as light-yellow gum (3.1 mg, 17%). ): 421.4 (MH+).

Example 87 -Butyl[(S)(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl[(R)(2-chlorophenyl )-ethyl](3,3-difluoro-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 87), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidin- 1-yl)-3H-[1,2,3]triazolo[4,5-d] dine and (R)(2-chlorophenyl)ethanol and isolated as light-yellow gum (3.8 mg, 21%). MS(m/e): 421.4 (MH+).

Example 88 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl]- 1-phenyl-ethanol N N A mixture of 2-(5-tert-butyl(3,3-difluoropyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)phenylethanone (6.0 mg, 15.0 µmol) and NaBH4 (1.7 mg, 45.0 µmol) in methanol(250 µL) was stirred at the room temperature for 1h. The reaction mixture was directly purified by preparative HPLC n: Gemini 5um C18 110A 75 x 30mm. mobile phase: water (0.05% Et3N): acetonitrile 72:25% to 5:95%. WL: 230 nm Flow: 30 mL/min.) to afford the title compound as white solid (2.3 mg, 38%). ): 403.4 (MH+).

Example 89 5-tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of -butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(bromomethyl)chlorofluorobenzene and isolated as light-yellow gum. MS(m/e): 425.3 (MH+).

Example 90 -tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- ]triazolo[4,5-d]pyrimidine F N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)chlorofluorobenzene and isolated as light-yellow gum. ): 425.3 (MH+).

Example 91 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)oxetanyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from -butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-bromooxetane and isolated as light-yellow gum.

MS(m/e): 339.3 (MH+).

Example 92 [5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl]-(2- chloro-phenyl)-methanone N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-chlorobenzoyl de and isolated as light-yellow solid. ): 421.3 (MH+).

Example 93 )[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl] hydroxymethyl-pyrrolidinol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (3S,5R)(hydroxymethyl)pyrrolidinol hydrochloride and isolated as white solid. MS(m/e): 417.3 (MH+).

Example 94 {(R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-4,4- difluoro-pyrrolidinyl}-methanol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (R)-(4,4-difluoropyrrolidinyl)methanol hydrochloride and isolated as white solid. MS(m/e): 437.3 (MH+).

Example 95 [5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-4,4- difluoro-pyrrolidinol N N F OH In y to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the titlecompound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (R)-4,4-difluoropyrrolidinol hydrochloride and ed as white solid. MS(m/e): 423.3 (MH+).

Example 96 -tert-Butyl(2,6-dichlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- ]triazolo[4,5-d]pyrimidine N N Cl N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo ]pyrimidine and 2-(bromomethyl)-1,3-dichlorofluorobenzene and isolated as white solid. MS(m/e): 459.2 (MH+).

Example 97 5-tert-Butyl(2-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from -butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-(bromomethyl)chloropyridine hydrobromide and isolated as light-yellow gum. MS(m/e): 408.3 (MH +).

Example 98 -tert-Butyl(3-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 4-chloro(chloromethyl)pyridine and isolated as light-yellow gum. MS(m/e): 408.3 (MH+).

Example 99 5-tert-Butyl(2,5-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- ]triazolo [4,5-d]pyrimidine and 2,5-dichloro(chloromethyl)pyridine and isolated as light-yellow gum. MS(m/e): 442.3 (MH+).

Example 100 -tert-Butyl(3,6-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N Cl N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3,6-dichloro(chloromethyl)pyridine and isolated as light-yellow gum. MS(m/e): 442.3 (MH+).

Example 101 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(4-methyl-furazanylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was ed from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- ]triazolo [4,5-d]pyrimidine and 3-(bromomethyl)methyl-1,2,5-oxadiazole and isolated as light-yellow gum. MS(m/e): 379.3 (MH+).

Example 102 -Butyl(3,3-difluoro-pyrrolidinyl)(3-methyl-[1,2,4]oxadiazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 5-(chloromethyl)methyl-1,2,4-oxadiazole and isolated as yellow gum. MS(m/e): 379.3 (MH+).

Example 103 5-tert-Butyl[2-(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(2-bromoethyl)chlorobenzene and ed as light-yellow gum. MS(m/e): 421.3 (MH+).

Example 104 -tert-Butyl[2-(3-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(2-bromoethyl)chlorobenzene and isolated as light-yellow gum. MS(m/e): 421.3 (MH+). e 105 5-tert-Butyl[2-(4-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(2-bromoethyl)chlorobenzene and isolated as light-yellow gum. MS(m/e): 421.3 (MH+).

Example 106 (S)[5-tert-Butyl(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinol N N In analogy to the procedure described for the synthesis of 4-(5-tert-butyl(4- ybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholine (example 58, step c), the title compound was prepared from -butylchloro(4-methoxybenzyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and (S)-pyrrolidinol and isolated as light-yellow solid.

MS(m/e): 383.3 (MH+).

Example 107 -tert-Butyl(2-chloro-benzenesulfonyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine S O N N In analogy to the procedure bed for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-chlorobenzenesulfonyl chloride and isolated as brown solid. MS(m/e): 457.3 (MH+).

Example 108 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(R)-tetrahydro-furanyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In y to the procedure bed for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and (S)-tetrahydrofuranol and isolated as colorless gum. MS(m/e): 353.3 (MH+).

Example 109 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(S)-tetrahydro-furanyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of -butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and (R)-tetrahydrofuranol and isolated as colorless gum. MS(m/e): 353.3 (MH+).

Example 110 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] (2-chloro-phenyl)-ethanone N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was ed from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-bromo(2-chlorophenyl)ethanone and isolated as yellow gum. MS(m/e): 435.3 (MH+).

Example 111 5-tert-Butyl(2,3-dichlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N F N In analogy to the procedure described for the sis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was ed from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)-3,4-dichlorofluorobenzene and isolated as white solid. MS(m/e): 459.3 (MH+).

Example 112 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methanesulfonyl-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 1-(bromomethyl)(methylsulfonyl)benzene and isolated as white solid. ): 451.3 (MH+).

Example 113 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-pyridinyl-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(2-bromoethyl)pyridine hydrobromide and isolated as ess gum. MS(m/e): 387.4 (MH+).

Example 114 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-methyl-oxetanylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- ]triazolo [4,5-d]pyrimidine and 3-(iodomethyl)methyloxetane and ed as white solid. MS(m/e): 367.3 (MH+).

Example 115 ert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] (3-chloro-phenyl)-ethanone N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-bromo(3-chlorophenyl)ethanone and isolated as white solid. MS(m/e): 435.3 (MH+).

Example 116 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] oro-phenyl)-ethanone N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from -butyl(3,3-difluoropyrrolidinyl)-3H- ]triazolo [4,5-d]pyrimidine and 2-bromo(4-chlorophenyl)ethanone and isolated as light-yellow solid. MS(m/e): 435.3 (MH+).

Example 117 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] pyridinyl-ethanone N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-bromo(pyridinyl)ethanone hydrobromide and isolated as light-yellow solid. MS(m/e): 402.3 (MH+).

Example 118 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] pyridinyl-ethanone N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- ropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-bromo(pyridinyl)ethanone hydrobromide and isolated as light-red solid. ): 402.3 (MH+).

Example 119 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,3,6-trichloro-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N Cl N In analogy to the ure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)-1,3,4-trichlorobenzene and isolated as white solid. MS(m/e): 475.3 (MH+).

Example 120 -tert-Butyl(2-chlorotrifluoromethyl-benzyl)(3,3-difluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine F F N N In analogy to the procedure described for the sis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo ]pyrimidine and 1-(bromomethyl)chloro (trifluoromethyl)benzene and isolated as light-yellow solid. MS(m/e): 475.2 (MH+).

Example 121 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-pyridinyl-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N F In analogy to the procedure described for the synthesis of -butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-(2-bromoethyl)pyridine hydrobromide and ed as white solid. MS(m/e): 388.3 (MH+).

Example 122 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-pyridinyl-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from -butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 4-(2-bromoethyl)pyridine hydrobromide and isolated as brown solid. MS(m/e): 388.3 (MH+).

Example 123 -tert-Butyl(2,3-dichlorotrifluoromethyl-benzyl)(3,3-difluoro-pyrrolidin yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine F F N N Cl N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was ed from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)-3,4-dichloro (trifluoromethyl)benzene and isolated as white solid. MS(m/e): 509.3 (MH+).

Example 124 -tert-Butyl(3,4-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N F In y to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(bromomethyl)-3,4-dichloropyridine hydrobromide and isolated as white solid. MS(m/e): 442.2 (MH+).

Example 125 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(1,1-dioxo-1λ6-thietanyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In y to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-bromo-thietane 1,1-dioxide and isolated as white solid. MS(m/e): 387.3 (MH+).

Example 126 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(1,1-dioxo-tetrahydro-1λ6-thiophen yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N F In analogy to the ure described for the synthesis of -butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-bromo-tetrahydro-thiophene 1,1-di oxide and isolated as white solid. MS(m/e): 401.3 (MH+).

Example 127 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl] nyl-ethanone N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-bromo(pyridinyl)ethanone hydrobromide and isolated as dark-brown solid. MS(m/e): 402.3 (MH+).

Example 128 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(5-methyl-[1,3,4]oxadiazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-(chloromethyl)methyl-1,3,4-oxadiazole and isolated as colorless gum. MS(m/e): 379.3 (MH+).

Example 129 -tert-Butyl(3-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 4-(bromomethyl)chloropyridine hydrobromide and ed as yellow gum. MS(m/e): 408.3 (MH+).

Example 130 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(5-methyl-[1,2,4]oxadiazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In y to the procedure described for the sis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-(chloromethyl)methyl-1,2,4-oxadiazole and isolated as yellow gum. MS(m/e): 379.3 (MH+).

Example 131 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(1-methyl-1H-tetrazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N N N In analogy to the procedure described for the sis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and oromethyl)methyl-1H-tetrazole and isolated as white solid. MS(m/e): 379.3 (MH+).

Example 132 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methyl-2H-[1,2,4]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and oromethyl)methyl-1H-1,2,4-triazole hydrochloride and isolated as colorless gum. MS(m/e): 378.3 (MH+).

Example 133 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(5-methanesulfonylmethyl-4H- [1,2,4]triazolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine O O N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-(iodomethyl)methyl(methylsulfonyl)-4H- 1,2,4-triazole and isolated as white solid. MS(m/e): 456.3 (MH+). e 134 {3-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin ylmethyl]chloro-pyridinyl}-dimethyl-amine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from -butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-(bromomethyl)chloro-N,N-dimethylpyridin amine hydrobromide and ed as light-yellow gum. MS(m/e): 451.4 (MH+).

Example 135 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-trifluoromethyl-1H-pyrazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine F F N N Step 1: 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-trifluoromethyltrityl-1H-pyrazol yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine F F N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was ed from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 4-(bromomethyl)(trifluoromethyl)trityl-1H- pyrazole and used in the next step without further purification.

Step 2: A mixture of crude 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-trifluoromethyl -1H-pyrazolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine, triethylsilane in TFA was stirred at room temperature for 3 h, concentrated and subjected to purification with preparative HPLC on reversed phase eluting with a gradient formed from acetonitrile, water and NEt3. After evaporation of the t containing fractions the title compound was isolated as white solid. MS(m/e): 431.3 (MH+).

Example 136 (S)[5-tert-Butyl(4-methyl-furazanylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N Step 1: Trifluoro-acetic acid (5-tert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- pyrrolidinyl-ester N N F O F O A mixture of (S)[5-tert-Butyl(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol (example 106) and triethylsilane in TFA was heated to 70 °C for 22h and evaporated to dryness. The residue was used without further purification in the utive step.

Step 2: In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from -butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-(bromomethyl)methyl-1,2,5-oxadiazole. After completion of the substitution reaction methanol was added and the e was stirred for 1 h at room temperature and subsequently subjected to purification with preparative HPLC on reversed phase eluting with a gradient formed from acetonitrile, water and NEt3. After evaporation of the product containing fractions the title compound was isolated as light- yellow gum. MS(m/e): 359.3 (MH+).

Alternative conditions: Step 1: -(5-tert-butyl-3H-triazolo[4,5-d]pyrimidinyl)pyrrolidinol . n HCl . n HCl (S)(3-benzyltert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (176 g, 494 mmol, Eq: 1.00) was dissolved in Methanol (2.09 kg, 2.64 l). 1.25 M HCl in Methanol (396 ml, 494 mmol, Eq: 1.00) was added followed by 10% Pd/C (34.7 g, 32.6 mmol, Eq: 0.066). The reaction mixture enated > 20h at 60°C / 1 bar. The reaction mixture was cooled evacuated, purged and filtered. The light yellow solution was concentrated at 50°C to ca 1 L. Toluene (1.3 kg, 1.5 l) was added and the on was concentrated at 50°C / 150 mbar to ca 1.2 kg to remove most of the methanol upon which the product started to crystallize. The white suspension was cooled to RT, stirred for 1h and filtered The filter cake was washed with Toluene and dried at 50°C/5 mbar to give 140.5 g of the title compound as a white solid. From microanalysis data, the structure would be consistent with a hemi hydrochloride.

Step 2: -[5-tert-butyl[(4-methyl-1,2,5-oxadiazolyl)methyl]triazolo[4,5- d]pyrimidinyl]pyrrolidinol N N (S)(5-tert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol . n HCl (4.25 g) was dissolved in DMF (20.1 g, 21.2 ml). DBU (5.47 g, 5.41 ml) was added dropwise over -10 min. A solution of 3-(bromomethyl)methyl-1,2,5-oxadiazole (3.78 g) in DMF (20.1 g, 21.2 ml) was added dropwise over 30 min. After 1h, the reaction mixture was added to 25% aqueous NH4Cl (85.0 ml). MTBE (126 g, 170 ml) was added. The s phase was separated and extracted with organic phase was separated and extracted with (126 g, 170 ml). The org phase was washed sequentially with water (85.0 g, 85.0 ml) and half ted aqueous NaCl (85.0 ml). The organic phases were combined, dried over MgSO4 and concentrated at 45°C/10 mbar to give 5.67 g of crude product a light yellow oil (mixture of isomers ca 2:1 by HPLC at 220 nm desired : undesired). The crude product was purified by ative SFC, column: Viridis 2-Ethyl-Pyridine, 5 um, 3 x 25 cm, 40°C, 15% EtOH/85% CO2sc, UV detection @ 260nm, to give 2.16 g of the title compound.

Example 137 (S)[5-tert-Butyl(3-methyl-[1,2,4]oxadiazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N In analogy to the ure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol le 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 5- (chloromethyl)methyl-1,2,4-oxadiazole and isolated as brown gum. MS(m/e): 359.3 (MH+).

Example 138 (S)[5-tert-Butyl(3-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N OH In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 3- chloro(chloromethyl)pyridine and isolated as brown gum. MS(m/e): 388.3 (MH+). e 139 (S)[5-tert-Butyl(3,6-dichloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N Cl N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 3,6- dichloro(chloromethyl)pyridine as yellow gum. MS(m/e): 422.3 (MH+).

Example 140 [5-tert-Butyl(2-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 3- (bromomethyl)chloropyridine hydrobromide as light-brown gum. ): 388.3 (MH+).

Example 141 (S)[5-tert-Butyl(2,3-dichloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title nd was prepared from trifluoro-acetic acid (5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 1- (bromomethyl)-2,3-dichlorobenzene as colorless gum. MS(m/e): 421.3 (MH+).

Example 142 (S)[5-tert-Butyl(2-trifluoromethyl-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin rrolidinol F F N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 1- (bromomethyl)(trifluoromethyl)benzene as light-yellow gum. MS(m/e): 421.3 (MH+).

Example 143 (S)[5-tert-Butyl(2-methanesulfonyl-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl]-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 1- (bromomethyl)(methylsulfonyl)benzene as colorless gum. MS(m/e): 431.3 (MH+). e 144 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,5-dimethyl-2H-pyrazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of -butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from -butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 5-(chloromethyl)-1,3-dimethyl-1H-pyrazole and isolated as light-yellow gum. MS(m/e): 391.3 (MH+).

Example 145 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-methyl-3H-[1,2,3]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 5-(chloromethyl)methyl-1H-1,2,3-triazole hydrochloride and isolated as light-yellow gum. MS(m/e): 378.3 (MH+).

Example 146 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(4,5-dimethyl-4H-[1,2,4]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the sis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and oromethyl)-4,5-dimethyl-4H-1,2,4-triazole and isolated as light-yellow solid. MS(m/e): 392.3 (MH+).

Example 147 -Butyl(3,3-difluoro-pyrrolidinyl)(2-methyloxy-pyridinylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the sis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3-(chloromethyl)methylpyridine 1-oxide and isolated as light-yellow gum. MS(m/e): 404.2 (MH+).

Example 148 (S)[5-tert-Butyl(3,4-dichloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- ]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 2- (bromomethyl)-3,4-dichloropyridine hydrobromide as white solid. MS(m/e): 422.3 (MH+).

Example 149 (S)[5-tert-Butyl(5-methyl-[1,2,4]oxadiazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from oro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 3- (chloromethyl)methyl-1,2,4-oxadiazole as light-yellow gum. ): 359.3 (MH+).

Example 150 (S)[5-tert-Butyl(5-methyl-[1,3,4]oxadiazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 2- (chloromethyl)methyl-1,3,4-oxadiazole as light-yellow gum. MS(m/e): 359.5 (MH+). e 151 (S)[5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N In analogy to the procedure bed for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 5- (chloromethyl)methyl-1H-tetrazole as light-yellow gum. MS(m/e): 359.2 (MH+).

Alternative conditions: (S)(5-tert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol . n HCl (5 g) was dissolved in DMF (23.7 g, 25.0 ml). DBU (6.43 g, 6.37 ml) was added dropwise over -10 min. A solution of 5-(chloromethyl)methyl-1H-tetrazole (3.33 g) in DMF (23.7 g, 25.0 ml) was added se over 35 min at RT. The orange solution was stirred for 2h.

The reaction mixture was added to 25% aqueous NH4Cl (100 ml). MTBE (148 g, 200 ml) was added. The aqueous phase was separated and ted with MTBE (148 g, 200 ml).

The organic phases were washed sequentially with water (100 g, 100 ml) and half saturated NaCl (100 ml). Then the organic phases were combined dried over MgSO4 and evaporated at 45°C/ down to 10 mbar to give 5.75 g of crude product as a white foam. 3.6 g of the crude product was purified by preparative SFC, : Kromasil 60 SIL, 5 um, 21.2 x 250 mm, 80% CO2/20% MeOH, 40°C to give 1.98 g of the product.

Crystallization: 1.3 g of the product was llized from iPrOAc/Heptane (ca 1:1) to give 1.2 g of product as a white powder (seed crystals were obtained from test tube cryst. tests in iPrOAcHeptane and tAmOH/heptane mixture).

Example 152 (S)[5-tert-Butyl(2-methyl-2H-[1,2,4]triazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from oro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 5- (chloromethyl)methyl-1H-1,2,4-triazole hydrochloride as colorless gum. MS(m/e): 358.2 (MH+).

Example 153 (S)[5-tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol N N OH In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester le 136, step 1) and 3- (chloromethyl)-4,5-dimethyl-4H-1,2,4-triazole hydrochloride as white solid. MS(m/e): 372.4 (MH+).

Example 154 (S)[5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 5- (chloromethyl)methyl-1H-1,2,3-triazole hydrochloride as light-yellow gum. MS(m/e): 358.2 (MH+).

Example 155 [5-tert-Butyl(2,5-dimethyl-2H-pyrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 5- omethyl)-1,3-dimethyl-1H-pyrazole as white solid. ): 371.3 (MH+).

Example 156 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-trifluoromethyl-[1,2,4]oxadiazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine F F N N In analogy to the procedure bed for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 5-(chloromethyl)(trifluoromethyl)-1,2,4- oxadiazole and isolated as brown gum. MS(m/e): 433.3 (MH+).

Example 157 -Butyl(1-cyclopropyl-1H-tetrazolylmethyl)(3,3-difluoro-pyrrolidin yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N F In analogy to the procedure described for the synthesis of -butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 5-(chloromethyl)cyclopropyl-1H-tetrazole and isolated as red gum. MS(m/e): 405.3 (MH+).

Example 158 (S){5-tert-Butyl[2-(7-nitro-benzo[1,2,5]oxadiazolylamino)-pyridin ylmethyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl}-pyrrolidinol O + O N N A mixture of (S)[5-tert-Butyl(2-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol le 140) (5.30 mg, 13.7 µmol), 7- nitrobenzo[c][1,2,5]oxadiazolamine (2.95 mg, 16.4 µmol), Pd2(dba)3 (1.25 mg, 1.37 µmol), xantphos (2.15 mg, 3.71 µmol) and Cs2CO3 (8.06 mg, 24.8 µmol) in dioxane (500 µl) was heated to 120 °C and d for 20 min. The crude material was filtered (celite), concentrated and purified by preparative HPLC eluting with a gradient formed from acetonitrile, water and NEt3. The product containing fractions were evaporated to yield 1.2 mg (16%) of the title compound as red solid. MS(m/e): 532.4 (MH+).

Example 159 )[5-tert-Butyl(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- 2-hydroxymethyl-pyrrolidinol N N In analogy to the procedure described for the synthesis of 4-(5-tert-butyl(4- methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholine (example 58, step c), the title compound was ed from 5-tert-butylchloro(4-methoxybenzyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and (2S,3S)(hydroxymethyl)pyrrolidinol hydrochloride and isolated as yellow gum. MS(m/e): 413.4 (MH+).

Example 160 (S)[5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol le 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 5- (chloromethyl)cyclopropyl-1H-tetrazole as light-yellow gum. MS(m/e): 385.3 (MH+).

Example 161 (S)[5-tert-Butyl(2,5-dimethyl-2H-[1,2,4]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 5- omethyl)-1,3-dimethyl-1H-1,2,4-triazole as colorless gum. MS(m/e): 372.3 (MH+).

Example 162 (S)[5-tert-Butyl(2-methyloxy-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- midinyl]-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (S)(5-tert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinyl-ester (example 136, step 1) and 3- (chloromethyl)methylpyridine 1-oxide as light yellow solid. MS(m/e): 384.3 (MH+).

Example 163 -tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,5-dimethyl-2H-[1,2,4]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In y to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-butyl(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 5-(chloromethyl)-1,3-dimethyl-1H-1,2,4-triazole and isolated as light-yellow gum. MS(m/e): 392.3 (MH+).

Example 164 )[5-tert-Butyl(4-methyl-furazanylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol N N Step 1: Trifluoro-acetic acid (2S,3S)(5-tert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester N N F O F F F O A mixture of (2S,3S)(5-tert-butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)(hydroxymethyl)pyrrolidinol (example 159) (9.0 mg, 21.8 µmol) and triethylsilane (7.61 mg, 10.5 µl, 65.5 µmol) in TFA (200 µl) heated to 70 °C and stirred for 21 h. The on mixture was concentrated in vacuo and used without further purification in the consecutive step.

Step 2: In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (2S,3S)(5-tert-butyl- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester (example 164, step 1) and 3-(bromomethyl)methyl-1,2,5-oxadiazole as light yellow gum. MS(m/e): 389.3 (MH+).

Example 165 )[5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- midinyl]hydroxymethyl-pyrrolidinol N N OH In analogy to the procedure described for the synthesis of [5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (2S,3S)(5-tert-butyl- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester (example 164, step 1) and 5-(chloromethyl)methyl-1H-tetrazole as white solid.

MS(m/e): 389.3 (MH+).

Example 166 (2S,3S)[5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]hydroxymethyl-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (2S,3S)(5-tert-butyl- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester (example 164, step 1) and 5-(chloromethyl)cyclopropyl-1H-tetrazole as lightyellow solid. MS(m/e): 415.4 (MH+).

Example 167 (2S,3S)[5-tert-Butyl(3-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol le 136) the title compound was prepared from oro-acetic acid (2S,3S)(5-tert-butyl- 2,3]triazolo[4,5-d]pyrimidinyl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester (example 164, step 1) and 3-chloro(chloromethyl)pyridine as red gum. MS(m/e): 418.3 (MH+).

Example 168 (2S,3S)[5-tert-Butyl(2-methanesulfonyl-benzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methyl- furazanylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (2S,3S)(5-tert-butyl- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester (example 164, step 1) and momethyl)(methylsulfonyl)benzene as white solid. MS(m/e): 461.3 (MH+).

Example 169 (2S,3S)[5-tert-Butyl(2-methyl-2H-[1,2,4]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]hydroxymethyl-pyrrolidinol N N N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methyl- furazanylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was ed from oro-acetic acid (2S,3S)(5-tert-butyl- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester (example 164, step 1) and 5-(chloromethyl)methyl-1H-1,2,4-triazole hydrochloride as white solid. MS(m/e): 388.3 (MH+).

Example 170 (2S,3S)[5-tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]hydroxymethyl-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (2S,3S)(5-tert-butyl- 2,3]triazolo[4,5-d]pyrimidinyl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester (example 164, step 1) and 3-(chloromethyl)-4,5-dimethyl-4H-1,2,4-triazole hydrochloride as white solid. MS(m/e): 402.4 (MH+). e 171 (2S,3S)[5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]hydroxymethyl-pyrrolidinol N N In analogy to the procedure described for the synthesis of (S)[5-tert-Butyl(4-methylfurazanylmethyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid )(5-tert-butyl- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester (example 164, step 1) and 5-(chloromethyl)methyl-1H-1,2,3-triazole hydrochloride as light-yellow solid. MS(m/e): 388.3 (MH+).

Example 172 (2S,3S)[5-tert-Butyl(2-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol N N In analogy to the procedure described for the sis of (S)[5-tert-Butyl(4-methylfurazanylmethyl 1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol (example 136) the title compound was prepared from trifluoro-acetic acid (2S,3S)(5-tert-butyl- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)(2,2,2-trifluoro-acetoxymethyl)-pyrrolidinyl ester (example 164, step 1) and 3-(bromomethyl)chloropyridine hydrobromide as white solid. MS(m/e): 418.3 (MH+).

Example 173 -tert-Butyl(4-methyl-furazanylmethyl)(3,3,4,4-tetrafluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine N N F F F F Step 1: -tert-Butyl(4-methoxy-benzyl)(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N F F F F In analogy to the procedure described for the synthesis of 4-(5-tert-butyl(4- methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholine (example 58, step c), the title compound was prepared from 5-tert-butylchloro(4-methoxybenzyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 3,3,4,4-tetrafluoropyrrolidine hydrochloride and used without further purification in the consecutive step.

Step 2: 5-tert-Butyl(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N F F F F The crude 5-tert-Butyl(4-methoxy-benzyl)(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- ]triazolo[4,5-d]pyrimidine was treated with triethylsilane in TFA and heated to 70 °C for 20 h and evaporated. The crude al was used without further purification in the consecutive step.

Step 3: In analogy to the procedure bed for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was prepared from 5-tert-Butyl(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 3-(bromomethyl)methyl-1,2,5-oxadiazole and isolated as light-yellow gum. ): 415.3 (MH+).

Example 174 -tert-Butyl(3-methyl-[1,2,4]oxadiazolylmethyl)(3,3,4,4-tetrafluoro- pyrrolidinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N F F F F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 5-(chloromethyl)methyl-1,2,4-oxadiazole and isolated as light-yellow gum. MS(m/e): 415.3 (MH+). e 175 -tert-Butyl(5-methyl-[1,3,4]oxadiazolylmethyl)(3,3,4,4-tetrafluoropyrrolidinyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N F F F F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- ropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 2-(chloromethyl)methyl-1,3,4-oxadiazole and isolated as light-yellow gum. MS(m/e): 415.3 (MH+).

Example 176 -Butyl(1-methyl-1H-tetrazolylmethyl)(3,3,4,4-tetrafluoro-pyrrolidin yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N F F F F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 5-(chloromethyl)methyl-1H-tetrazole and isolated as yellow solid. MS(m/e): 415.3 (MH+).

Example 177 -Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)(3,3,4,4-tetrafluoropyrrolidinyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N F F F F In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title nd was prepared from 5-tert-Butyl(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 3-(chloromethyl)-4,5-dimethyl-4H-1,2,4-triazole hydrochloride and isolated as white solid. MS(m/e): 428.3 (MH+).

Example 178 -tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)(3,3,4,4-tetrafluoro- pyrrolidinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N F F F F In analogy to the procedure bed for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(3,3,4,4-tetrafluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 5-(chloromethyl)methyl-1H-1,2,3-triazole hydrochloride and isolated as light-yellow gum. MS(m/e): 414.3 (MH+).

Example 179 -Butyl(4-methyl-furazanylmethyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N O Step 1: -tert-Butyl(4-methoxy-benzyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the sis of 4-(5-tert-butyl(4-methoxy benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholine (example 58, step c), the title compound was prepared from 5-tert-butylchloro(4-methoxybenzyl)-3H- [1,2,3]triazolo [4,5-d]pyrimidine and 2-oxaazaspiro[3.3]heptane oxalate and used without further purification in the consecutive step.

Step 2: [1-(5-tert-Butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)chloromethyl-azetidinyl]- N N A mixture of crude 6-(5-tert-butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)oxaazaspiro[3.3]heptane (example 179, step 1) (361 mg, 915 µmol) and palladium (II) de (81.1 mg, 458 µmol) in MeOH (3.00 mL) was d at room temperature for 9 h under H2 (1 atm) atmosphere. The mixture was filtered through cotton and concentrated in vacuo. The residue was used without further purification in the consecutive step.

Step 3: -tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N A mixture of (1-(5-tert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) (chloromethyl)azetidinyl)methanol (284 mg, 915 µmol) le 179, step 2) and potassium tert-butoxide (205 mg, 1.83 mmol) in THF (3 mL) at 0 °C was stirred to room temperature and stirred for 20 h. The mixture was filtered, trated in vacuo and used without further purification in the consecutive step.

Step 4: In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and momethyl)methyl-1,2,5-oxadiazole and isolated as white solid. MS(m/e): 371.3 (MH+).

Example 180 5-tert-Butyl(3-methyl-[1,2,4]oxadiazolylmethyl)(2-oxaaza-spiro[3.3]hept yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 5-(chloromethyl)methyl-1,2,4-oxadiazole and isolated as light-red solid. MS(m/e): 371.2 (MH+).

Example 181 5-tert-Butyl(5-methyl-[1,3,4]oxadiazolylmethyl)(2-oxaaza-spiro[3.3]hept yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of -butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 2-(chloromethyl)methyl-1,3,4-oxadiazole and isolated as white solid. MS(m/e): 371.2 (MH+).

Example 182 -tert-Butyl(1-methyl-1H-tetrazolylmethyl)(2-oxaaza-spiro[3.3]heptyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In y to the procedure bed for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 5-(chloromethyl)methyl-1H-tetrazole and isolated as white solid. MS(m/e): 371.3 (MH+).

Example 183 5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)(2-oxaaza-spiro[3.3]hept- 6-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure bed for the synthesis of 5-tert-butyl(3,3- ropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 5-(chloromethyl)cyclopropyl-1H-tetrazole and isolated as white solid. MS(m/e): 397.3 (MH+).

Example 184 -tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)(2-oxaaza- spiro[3.3]heptyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- ropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 3-(chloromethyl)-4,5-dimethyl-4H-1,2,4-triazole hydrochloride and isolated as white solid. MS(m/e): 384.3 (MH+).

Example 185 5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)(2-oxaaza-spiro[3.3]hept- 6-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 61), the title compound was prepared from 5-tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and oromethyl)methyl-1H-1,2,3-triazole hydrochloride and isolated as white solid. MS(m/e): 370.2 (MH+).

Example 186 -tert-Butyl(2-methanesulfonyl-benzyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure bed for the synthesis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), the title compound was prepared from 5-tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 1-(bromomethyl)(methylsulfonyl)benzene and isolated as white solid. MS(m/e): 443.3 (MH+).

Example 187 -tert-Butyl(3-chloro-pyridinylmethyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the sis of 5-tert-butyl(3,3- difluoropyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 61), the title compound was prepared from 5-tert-Butyl(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine and 3-chloro(chloromethyl)pyridine and isolated as light-brown gum. MS(m/e): 400.3 (MH+).

Example 188 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinone N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and pyrrolidinone. ): 385.3 (MH+).

Example 189 -tert-Butyl(2-chloro-benzyl)(3,3-dimethyl-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of -butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- ]triazolo[4,5-d] pyrimidine and 3,3-dimethylpyrrolidine. MS(m/e): 399.4 (MH+).

Example 190 {1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-methyl-amine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and N-methylpyrrolidinamine. MS(m/e): 400.3 (MH+). e 191 {1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-dimethyl-amine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was ed from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] dine and N,N-dimethylpyrrolidinamine. MS(m/e): 414.3 (MH+).

Example 192 N-{(S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-acetamide N N H In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (S)-N-(pyrrolidinyl)acetamide. MS(m/e): 428.3 (MH+). e 193 N-{(R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-acetamide N N In analogy to the procedure bed for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (R)-N-(pyrrolidinyl)acetamide. ): 428.3 (MH+).

Example 194 N-{1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-N-methyl-acetamide N N O In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and N-methyl-N-(pyrrolidinyl)acetamide. MS(m/e): 442.4 (MH+).

Example 195 -tert-Butyl(2-chloro-benzyl)(3-phenyl-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N In analogy to the ure described for the synthesis of -butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3-phenylpyrrolidine. ): 447.4 (MH+).

Example 196 N-{1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-N-ethyl-acetamide N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and N-ethyl-N-(pyrrolidinyl)acetamide. MS(m/e): 456.5 (MH+).

Example 197 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-azetidine- 3-carboxylic acid methyl ester N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and methyl azetidinecarboxylate. MS(m/e): 415.3 (MH+).

Example 198 -Butyl(2-chloro-benzyl)(3-methyl-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N In analogy to the procedure bed for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3-methylpyrrolidine hydrochloride. MS(m/e): 385.3 (MH+).

Example 199 C-{(S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-methylamine N N N NH In analogy to the procedure bed for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and (S)-pyrrolidinylmethanamine. ): 400.4 (MH+).

Example 200 -tert-Butyl(2-chloro-benzyl)[2-(1-methyl-1H-pyrazolyl)-pyrrolidinyl]-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] dine and 1-methyl(pyrrolidinyl)-1H-pyrazole. MS(m/e): 451.4 Example 201 -tert-Butyl(2-chloro-benzyl)[2-(2-methyl-2H-pyrazolyl)-pyrrolidinyl]-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In y to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 1-methyl(pyrrolidinyl)-1H-pyrazole. MS(m/e): 451.4 Example 202 -tert-Butyl(2-chloro-benzyl)[2-(3-methyl-isoxazolyl)-pyrrolidinyl]-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- holinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3-methyl(pyrrolidinyl)isoxazole. MS(m/e): 452.4 Example 203 -tert-Butyl(2-chloro-benzyl)[2-(3-methyl-[1,2,4]oxadiazolyl)-pyrrolidin yl]-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title nd was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and 3-methyl(pyrrolidinyl)-1,2,4-oxadiazole.

MS(m/e): 453.4 Example 204 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- idinol N N In analogy to the procedure described for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and pyrrolidinol. MS(m/e): 387.4 Example 205 -tert-Butyl(2-chloro-benzyl)cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N A mixture of cyclobutanol (173 mg, 2.4 mmol) and NaH (4.8 mg, 0.12mmol) in DMF (1 mL) was stirred for 30 min at room temperature. 5-tert-butylchloro(2-chlorobenzyl)- 3H-[1,2,3]triazolo[4,5-d] pyrimidine (26.9 mg, 0.08 mmol) was added and the mixture was d at room temperature overnight. Formic acid added and the mixture was subjected to preparative HPLC purification on reversed phase eluting with a gradient formed from acetonitrile, water and formic acid. The product containing fractions were evaporated to yield 4 mg (13 %) of the title compound. MS(m/e): 372.3.

Example 206 5-tert-Butyl(2-chloro-benzyl)(oxetanyloxy)-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N In y to the ure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and oxetanol. MS(m/e): 374.3.

Example 207 -tert-Butyl(2-chloro-benzyl)methoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and methanol. MS(m/e): 332.2.

Example 208 -Butyl(2-chloro-benzyl)ethoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title compound was prepared from -butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and ethanol. MS(m/e): 346.2.

Example 209 -tert-Butyl(2-chloro-benzyl)isopropoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title nd was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and propanol. MS(m/e): 360.2.

Example 210 -tert-Butyl(2-chloro-benzyl)cyclopropylmethoxy-3H-[1,2,3]triazolo[4,5- midine N N In analogy to the procedure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine le 205) the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and cyclopropylmethanol. MS(m/e): 372.3.

Example 211 -tert-Butyl(2-chloro-benzyl)(1-cyclopropyl-ethoxy)-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N In analogy to the ure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and 1-cyclopropylethanol. MS(m/e): 386.4.

Example 212 -tert-Butyl(2-chloro-benzyl)cyclopentyloxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine N N In analogy to the procedure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and cyclopentanol. MS(m/e): 386.3.

Example 213 -tert-Butyl(2-chloro-benzyl)(2,2-dimethyl-propoxy)-3H-[1,2,3]triazolo[4,5- d]pyrimidine N N In y to the procedure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title nd was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and 2,2-dimethylpropanol. ): 388.3.

Example 214 -tert-Butyl(2-chloro-benzyl)(2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N F F In analogy to the procedure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and 1,1,1-trifluoropropanol. MS(m/e): 414.2.

Example 215 -tert-Butyl(2-chloro-benzyl)((S)-2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N F F In analogy to the ure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title compound was ed from 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine and (S)-1,1,1-trifluoropropanol. MS(m/e): 414.3.

Example 216 -Butyl(2-chloro-benzyl)((R)-2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine N N F F In analogy to the procedure described for the synthesis of 5-tert-Butyl(2-chloro-benzyl)- 7-cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 205) the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d] dine and (R)-1,1,1-trifluoropropanol. MS(m/e): 414.3.

Example 217 -(3-benzyltert-butyl-triazolo[4,5-d]pyrimidinyl)pyrrolidinol N N Step 1 batch process: 5-aminobenzyl-triazolecarboxamide N NH N NH2 O Sodium azide (4.34 g, 66.0 mmol, Eq: 1.05) was charged in the reactor followed by DMSO (44.0 g, 40 ml) and Hunig's base (829 mg, 1.12 ml, 6.29 mmol, Eq: 0.1). The suspension was stirred for 10 min. at 25°C. (Chloromethyl)benzene (8 g, 7.29 ml, 62.9 mmol, Eq: 1.00) was added dropwise over 60 min at 25°C. After 3h at 25°C, water (1.6 g, 1.6 ml) was added, the reaction mixture was stirred for 30 min and was filtered. The residue was washed with DMSO (17.6 g, 16.0 ml). The obtained benzyl azide solution was used ly in the ddition step.

In a separate reactor, DMSO (17.6 g, 16.0 ml) was charged followed by, 32% aqueous NaOH (7.86 g, 5.82 ml, 62.9 mmol, Eq: 1.0) and water (5.00 g, 5.00 ml). A solution of 2- cyanoacetamide (7.93 g, 94.3 mmol, Eq: 1.50) in DMSO (17.6 g, 16.0 ml) was added dropwise over 15 min at 25°C. The usly prepared benzyl azide solution was added dropwise over 4h at 25°C. The reaction was d overnight at 25°C and water (120 g, 120 ml) was added dropwise over 30 min at 25°C (exothermic). The resulting suspension was cooled over 30 min to 0°C, stirred at 0°C for 30 min and filtered. The filter cake was washed with water (40.0 g, 40.0 ml) and was dried at 50°C/5 mbar to give 12.6g of the title compound.

Step 2 continuous process: 5-aminobenzyl-triazolecarboxamide N NH N NH2 Solution A: Benzyl azide solution preparation: Sodium azide (54.5 g, 829 mmol, Eq: 1.05) was charged in the reactor followed by DMSO (550 g, 500 ml). Water (37.5 ml) was added and the suspension was stirred at 40°C for 3- 4h. Hunig's base (10.4 g, 14.1 ml, 79.0 mmol, Eq: 0.1) was added and the suspension was cooled to Tj = 30-35°C. Benzyl chloride (100 g, 91.1 ml, 790 mmol, Eq: 1.00) was added dropwise over ca 1h. The reaction e was stirred ght at 30-35°C. The reaction was cooled to RT and filtered. The filter cake was washed twice with 40 mL DMSO to give 783 g of a light yellow solution (13.4 % m/m BnN3 solution, d = 1.086, 721 mL solution, 0.146 g / mL BnN3 solution) Solution B: 2-cyanoacetamide solution (prepared in excess): 120 g cyanoacetamide were dissolved in 327 mL DMSO d: 1.12 428 mL solution 0.28 g/mL Solution C: 32% aqueous NaOH Reactor design: The two first reactors are microreactor of type XXL from LTF GmbH and are connected in series. The first reactor is used to perform the mixing of the different reagents (the reagent streams are preheated in a ca 1 mL ter and then combined into a reactor volume of ca 2 mL), the second reactor is used as an additional residence time reactor (ca 5.5 mL volume). The eactor output stream is then connected to a CSTR cascade to provide additional residence time (a 20 mL then a 40 mL overflow r).

The microreactors and CSTR overflow rs are heated at 60-65°C.

Ca 85% conversion is achieved at the exit of the glass microreactor, ca 95% conversion within the first CSTR and > 99% conversion at the exit of the second CSTR. Higher conversion can be achieved at the exit of the microreactors by increasing the residence time but to the cost of the throughput.

It is preferable to premix the cyanoacetamide and the base prior to contacting with the BnN3 stream. Indeed the azide can decompose in a runaway manner when contacted with NaOH. The ity also depends on the substitution (the stability decrease dramatically going from p-methoxybenzyl azide to BnN3 to domethyl)chloro-benzene).

NaOH is also preferably used in stoichiometric or slightly sub-stoichiometric amounts.

This represents a lab scale solution and other setups are of course le, using other type of mixers/reactors for example standard static mixers (e.g. Kenics), CSTR cascades, coils, other type of glass or ceramic reactors and combination f which can be adapted depending on the desired throughput and scale.

Flows: A: 3.6 mL/min ; B: 1.88mL/min ; C:0.54 mL/min, which corresponds to a 1:1.5:1.4 equivalent ratio.

Run Summary: After a standard start-up procedure, the process was run for 3h07 corresponding to 735 g BnN3 solution (based on flow and gravimetric monitoring). The output stream was discharged in a new collection tank ca every hour. The pumps were switched to a wash solvent and the microreactor exit was switched to waste. Meanwhile, the on was continued for ca. 10 min in the overflow rs which were then emptied in the tion tank. The 3 collected fractions were transferred into a 3L jacketed reactor and 1.5L water was added over 5-10 min. The temperature rose from 25 to 43°C. The resulting suspension was stirred overnight at 25°C then cooled for 2.5 h at 0-5°C and filtered. The filter cake was washed three times with 100 ml water and dried at 50°C/5-10mbar to give 154 g of the title compound as a white powder.

Step 2: 3-benzyltert-butyl-4H-triazolo[4,5-d]pyrimidinone N NH NH 2 N N N N N N N NH NH N 2 N 2 N O O O -aminobenzyl-1H-1,2,3-triazolecarboxamide (150 g, 691 mmol, Eq: 1.00) was suspended in N,N-dimethylacetamide (512 g, 550 ml). Pyridine (82.1 g, 83.5 ml, 1.04 mol, Eq: 1.5) was added followed by pivaloyl chloride (126 g, 129 ml, 1.04 mol, Eq: 1.5) and the reaction e was heated to Tj = 80°C. After complete acylation (ca 1h30), KHCO3 (347 g, 3.45 mol, Eq: 5.00) was added and the suspension was heated to Tj = 155°C to convert the 1-benzyl(2,2-dimethylpropanoylamino)triazolecarboxamide ediate to the product. After 18h30 at 155°C, the reaction mixture was cooled to RT and water (3.48 kg, 3.48 l) was added dropwise within 30 Min. The light yellow suspension was d for 30 min at RT, 2h at 0°C and filtered. The filter cake was washed with cold (0- 5°C) water (600 g, 600 ml) and dried at 50°C/5 mbar to give 161.3 g of the title compound as an off-white powder. MS(m/e): 284.0 (MH+).

Step 3: yltert-butylchloro-triazolo[4,5-d]pyrimidine N N DMF over MS (105 g, 110 ml, 1.43 mol, Eq: 2.56) was d in the reactor followed by Dichlormethane (1.46 kg, 1.1 l). The solution was heated to 35°C and oxalylchloride (144 g, 97.6 ml, 1.11 mol, Eq: 2) was added over 1 h. After 45min, a fine suspension of 3- benzyltert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)-one (161 g, 557 mmol, Eq: 1.00) in a mixture of dichlormethane (877 g, 662 ml) and DMF (41.8 g, 44.1 ml) was added over of 20 min. After 3 h, the reaction mixture was cooled to RT and slowly added to a cold (0-5 °C) half saturated aqueous NaHCO3 (1.76 l). The organic phase was separated and washed again with half saturated NaHCO3 (662 ml) followed by water (662 g, 662 ml). Then the org. phase was dried over MgSO4 and was concentrated under reduced pressure at 50°C/down to 10 mbar to give 192 g of a crude oil which does crystallize on standing. The crude 3-benzyltert-butylchloro-triazolo[4,5-d]pyrimidine was introduced in the next step without further purification.

Step 4: (3S)(3-benzyltert-butyl-triazolo[4,5-d]pyrimidinyl)pyrrolidinol 3-benzyltert-butylchloro-3H-[1,2,3]triazolo[4,5-d]pyrimidine (192.2 g, 548 mmol, Eq: 1.00) was charged in the reactor followed by Acetonitrile (780 g, 1.0 l) and NEthyldiisopropylamine (108 g, 143 ml, 822 mmol, Eq: 1.5). (S)-Pyrrolidinol (54.1 g, 51.6 ml, 603 mmol, Eq: 1.1) was added dropwise over 30 min at Tr = 20 to < 30 °C. After 2h at 25°C, the reaction mixture was transferred with Toluene (865 g, 1.0 l) into a 3 l round bottom flask and it was concentrated on a rotary evaporator, to switch solvent to toluene. The toluene solution was washed with a 10% aqueous citric acid solution (1.0 l).

The aqueous phase was ted and extracted with toluene (434 g, 500 ml). The org. phases were washed sequentially with half saturated aqueous NaHCO3 (500 ml) and half saturated aqueous NaCl (500 ml). The org. phases were combined, dried over MgSO4 and trated at 45°C to ca 500 mL. e (684 g, 1.0 l) was added under stirring. After -10 min the t started to crystallize. The white suspension was stirred for 2h at RT and was filtered. The white filter cake was washed with heptane (274 g, 400 ml) and dried at 45°C/5 mbar to give 186.9 g of the title compound as a white powder. MS(m/e): 353.1 (MH+).

Example 218 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidin- 3-ol N N In analogy to the procedure bed for the synthesis of 5-tert-butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 5-tert-butylchloro(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d] pyrimidine and pyrrolidinol and isolated as ess foam.

MS(m/e): 387.4 (MH+).

Example 219 (R)(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)pyrrolidinol N N N a) (R)(3-Benzyltert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinol N N In analogy to the procedure described for the sis of -butyl(2-chlorobenzyl)- 7-morpholinyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 1, step c), the title compound was prepared from 3-benzyltert-butylchloro-triazolo[4,5-d]pyrimidine and (R)-pyrrolidinol and isolated as white foam. MS(m/e): 352.4 (MH+). b)(R)(5- tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinol (3-Benzyltert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- pyrrolidinol was hydrogenated over Pd/C and the resulting (R)(5-tert-Butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinol was reacted in analogy to the procedure described for the synthesis of 5-tert-butyl(3,3-difluoropyrrolidinyl) ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (example 61), with 5-(chloromethyl)methyl- 1H-tetrazole and isolated as white solid. MS(m/e): 359.2 (MH+).

Example 220 1-(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)pyrrolidinol N N N a) 1-(3-Benzyltert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinol N N In analogy to the procedure described for the synthesis of (R)(3-Benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinol (example 219, step a) the title compound was prepared from 3-benzyltert-butylchloro-triazolo[4,5-d]pyrimidine and pyrrolidinol and isolated as light yellow oil. b) 1-(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)pyrrolidinol In analogy to the procedure described for the synthesis of (5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) 1-(3-Benzyltert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidin- 3-ol was hydrogenated and subsequently reacted with 5-(chloromethyl)methyl-1H- tetrazole and isolated as light yellow oil. MS(m/e): 358.4 (MH+). e 221-a and Example 221- b (5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol and (R)(5-tert-butyl(2-chlorobenzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol Cl Cl N N N N N N N N N N N N OH OH a) 1-(3-Benzyltert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)methyl-pyrrolidin- 3-ol N N In analogy to the procedure bed for the synthesis of (3-Benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)-pyrrolidinol (example 219, step a) the title compound was ed from 3-benzyltert-butylchloro-triazolo[4,5-d]pyrimidine and 3-methyl-pyrrolidin-3and isolated as white solid and subjected to separation by chiral HPLC to yield (S)(3-benzyltert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol and (3-benzyltert-butyl-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol. The enatiopure intermediates where isolated with 39 % and 36 % yield. b) (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol and (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol In analogy to the ure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (R)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent on with 1-(bromomethyl)chlorobenzene. MS(m/e): 401.4 (MH+).

In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (S)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 1-(bromomethyl)chlorobenzene. MS(m/e): 401.4 (MH+).

Example 222-a and Example 222-b (S)(5-tert-butyl(2-(trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)methylpyrrolidinol and (R)(5-tert-butyl(2-(trifluoromethyl)benzyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol F F F F F F N N N N N N N N N N N N OH OH In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was ed from (S)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent on with 1-(bromomethyl)(trifluoromethyl)benzene. MS(m/e): 435.4 (MH+).

In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (R)(3-benzyltert-butyl-3H- ]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 1-(bromomethyl)(trifluoromethyl)benzene. MS(m/e): 435.4 (MH+).

Example 223-a and Example 223-b (5-tert-butyl(2-(methylsulfonyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)methylpyrrolidinol and (R)(5-tert-butyl(2-(methylsulfonyl)benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol O O S S O O N N N N N N N N N N OH OH In y to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title nd was prepared from (S)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through enation and subsequent reaction with 1-(bromomethyl)(methylsulfonyl)benzene. MS(m/e): 445.4 (MH+).

In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (R)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with momethyl)(methylsulfonyl)benzene. MS(m/e): 445.4 (MH+).

Example 224-a and Example 224-b (S)(5-tert-butyl((3-chloropyridinyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol and (R)(5-tert-butyl((3- chloropyridinyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol Cl Cl N N N N N N N N N N N N N N OH OH In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title nd was prepared from (S)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 3-chloro(chloromethyl)pyridine. MS(m/e): 402.4 (MH+).

In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (R)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and uent reaction with 3-chloro(chloromethyl)pyridine. MS(m/e): 402.4 (MH+). e 225-a and Example 225-b (S)(5-tert-butyl((5-methyl-1,3,4-oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol and (R)(5-tert-butyl((5-methyl-1,3,4- oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidin- 3-ol N N N N N N O N N N N N N N N OH OH In analogy to the procedure bed for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 2-(chloromethyl)methyl-1,3,4-oxadiazole. MS(m/e): 373.4 (MH+).

In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol le 219, step b) the title compound was prepared from (R)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 2-(chloromethyl)methyl-1,3,4-oxadiazole. MS(m/e): 373.4 (MH+).

Example 226-a and Example 226-b (S)(5-tert-butyl((3-methyl-1,2,4-oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol and (R)(5-tert-butyl((3-methyl-1,2,4- oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidin- 3-ol N N N N O O N N N N N N N N N N N N OH OH In analogy to the procedure described for the synthesis of (5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (S)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and uent on with 5-(chloromethyl)methyl-1,2,4-oxadiazole. MS(m/e): 373.4 (MH+).

In analogy to the procedure described for the sis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (R)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 5-(chloromethyl)methyl-1,2,4-oxadiazole. MS(m/e): 373.4 (MH+).

Example 227-a and Example 227-b (S)(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol and (R)(5-tert-butyl((1-methyl-1H- tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidin N N N N N N N N N N N N N N N N N N N N OH OH In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (S)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through enation and subsequent reaction with 5-(chloromethyl)methyl-1H-tetrazole. MS(m/e): 373.4 (MH+).

In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (R)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent on with 5-(chloromethyl)methyl-1H-tetrazole. ): 373.4 (MH+).

Example 228-a and e 228-b (S)(5-tert-butyl((4-methyl-1,2,5-oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol and (R)(5-tert-butyl((4-methyl-1,2,5- oxadiazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidin- 3-ol N N O O N N N N N N N N N N N N N N OH OH In analogy to the procedure bed for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (S)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 3-(bromomethyl)methyl-1,2,5-oxadiazole. MS(m/e): 373.4 (MH+).

In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was ed from (R)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 3-(bromomethyl)methyl-1,2,5-oxadiazole. MS(m/e): 373.4 (MH+).

Example 229-a and Example 229-b (S)(5-tert-butyl(3,3,3-trifluoropropyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 3-methylpyrrolidinol and (R)(5-tert-butyl(3,3,3-trifluoropropyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol F F F F F F N N N N N N N N N N N N OH OH In analogy to the procedure described for the sis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol le 219, step b) the title compound was prepared from (S)(3-benzyltert-butyl-3H- ]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 3-bromo-1,1,1-trifluoropropane. MS(m/e): 373.4 (MH+).

In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title nd was prepared from (R)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through hydrogenation and subsequent reaction with 3-bromo-1,1,1-trifluoropropane. ): 373.4 (MH+).

Example 230-a and Example 230-b (S)(5-tert-butyl((1-cyclopropyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol and (R)(5-tert-butyl((1-cyclopropyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol N N N N N N N N N N N N N N N N N N N N OH OH In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (S)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol h hydrogenation and subsequent reaction with 5-(chloromethyl)cyclopropyl-1H-tetrazole. MS(m/e): 399.4 (MH+).

In analogy to the procedure described for the synthesis of (R)(5-tert-butyl((1-methyl- 1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol (example 219, step b) the title compound was prepared from (R)(3-benzyltert-butyl-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol through enation and subsequent reaction with 5-(chloromethyl)cyclopropyl-1H-tetrazole. MS(m/e): 399.4 (MH+).

Example 231 Pharmacological tests The following tests were carried out in order to determine the ty of the nds of formula I: Radioligand binding assay The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended s of ne preparations (PerkinElmer) of human embryonic kidney (HEK) cells expressing the human CNR1 or CNR2 receptors in conjunction with 1.5 or 2.6 nM [3H]-CP-55,940 (Perkin Elmer) as radioligand, tively. Binding was performed in binding buffer (50 mM Tris, 5 mM MgCl2, 2.5 mM EDTA, and 0.5% l) fatty acid free BSA, pH 7.4 for CB1 receptor and 50 mM Tris, 5 mM MgCl2, 2.5 mM EGTA, and 0.1% (wt/vol) fatty acid free BSA, pH 7.4 for CB2 receptor) in a total volume of 0.2 ml for 1h at 30°C shaking. The reaction was terminated by rapid filtration through microfiltration plates coated with 0.5% polyethylenimine (UniFilter GF/B filter plate; Packard). Bound radioactivity was analyzed for Ki using nonlinear regression is (Activity Base, ID Business Solution, Limited), with the Kd values for [3H]CP55,940 determined from saturation experiments. The compounds of formula (I) show an excellent affinity for the CB2 or with affinitiesbelow 10 µM, more particularly of 1 nM to 3 µM and most particularly of 1nM to 100 nM.

The compounds according to formula (I) have an activity in the above assay (Ki) particularly of 0.5 nM to 10 µM, more particularly of 0.5 nM to 3 µM and most particularly of 0.5 nM to 100 nM. cAMP Assay CHO cells expressing human CB1 or CB2 receptors are seeded 17-24 hours prior to the experiment 50.000 cells per well in a black 96 well plate with flat clear bottom (Corning Costar #3904) in DMEM (Invitrogen No. 31331), 1x HT supplement, with 10 % fetal calf serum and incubated at 5% CO2 and 37°C in a humidified incubator. The growth medium was exchanged with Krebs Ringer Bicarbonate buffer with 1 mM IBMX and incubated at °C for 30 min. Compounds were added to a final assay volume of 100 µl and incubated for 30 min at 30 °C. Using the cAMP-Nano-TRF detection kit the assay (Roche Diagnostics) was stopped by the addition of 50 µl lysis reagent (Tris, NaCl, 1.5% Triton X100, 2.5% NP40, 10% NaN3) and 50 µl detection solutions (20 µM mAb Alexa700- cAMP 1:1, and 48 µM iumAHA-cAMP) and shaken for 2h at room temperature.

The time-resolved energy transfer is measured by a TRF reader (Evotec Technologies GmbH), equipped with a ND:YAG laser as excitation source. The plate is measured twice with the excitation at 355 nm and at the on with a delay of 100 ns and a gate of 100 ns, total re time 10s at 730 (bandwidth30 nm) or 645 nm (bandwidth 75 nm), respectively. The FRET signal is calculated as follows: FRET = T730-Alexa730-P(T645- B645) with P = Ru730-B730/Ru645-B645, where T730 is the test well measured at 730 nM, T645 is the test well measured at 645 nm, B730 and B645 are the buffer controls at 730 nm and 645 nm, respectively. cAMP content is determined from the function of a standard curve spanning from 10 µM to 0.13 nM cAMP.

EC50 values were determined using Activity Base analysis (ID Business Solution, Limited). The EC50 values for a wide range of inoid agonists generated from this assay were in agreement with the values hed in the scientific literature.

All compounds are CB2 agonists with EC50 below 3 uM and selectivity versus CB1 in the corresponding assay of at least 10 fold For example, the following nds showed the following human EC50 values in the functional cAMP assay described above: human CB2 EC50 human CB1 EC50 Example [µM] [µM] 1 0.0006 1.0641 2 0.0016 0.5552 3 0.0013 0.1598 4 0.0014 0.1902 0.0003 0.6318 6 0.0002 0.1648 7 0.0112 >10 8 0.6474 >10 9 0.0176 >10 0.0024 0.4039 11 0.0032 1.0938 12 0.0016 1.1067 human CB2 EC50 human CB1 EC50 [µM] [µM] 13 0.0123 >10 14 0.0021 1.2305 0.0032 0.9695 16 0.286 >10 17 0.0087 >10 18 0.0466 >10 19 0.0017 0.1312 0.0017 0.3463 21 0.0027 0.6011 22 0.0024 1.4993 23 0.0754 >10 24 0.003 0.4758 0.031 0.9191 26 0.0011 0.8661 27 0.0051 >10 28 0.0112 >10 29 0.0125 1.6317 0.0269 >10 31 0.0098 1.263 32 0.0207 >10 33 0.0025 0.764 human CB2 EC50 human CB1 EC50 [µM] [µM] 34 0.0275 2.2735 0.0036 >10 36 0.0006 0.4325 37 0.0003 0.4918 38 0.0182 0.3611 39 0.0079 1.332 40 0.0116 >10 41 0.0365 1.2194 42 0.0003 0.9908 43 0.0012 0.6261 44 0.001 >10 45 0.0522 >10 46 0.0044 2.3134 47 0.0202 >10 48 0.0083 >10 49 0.0011 0.1555 50 0.001 0.1394 51 0.0024 >10 52 0.0208 >10 53 0.015 >10 54 0.0028 >10 human CB2 EC50 human CB1 EC50 [µM] [µM] 55 0.0104 >10 56 0.0165 >10 57 0.0123 >10 58 0.3375 >10 59 0.0023 >10 60 0.0025 >10 61 0.0132 >10 62 0.0033 >10 63 0.0182 >10 64 0.0023 >10 65 0.0009 0.2202 66 0.002 >10 67 0.0002 0.1625 68 0.0007 >10 69 0.0003 0.276 70 0.0001 0.0508 71 0.0004 >10 72 0.0001 0.041 73 0.0001 0.0609 74 0.0001 0.0559 75 0.0002 0.0978 human CB2 EC50 human CB1 EC50 [µM] [µM] 76 0.0023 >10 77 0.0008 >10 78 0.0001 0.1433 79 0.0001 0.0823 80 0.0003 0.0693 81 0.0001 0.0689 82 0.0002 0.2523 83 0.0001 0.2834 84 0.0012 0.451 85 0.0002 >10 86 0.0004 0.371 87 0.001 0.2698 88 0.0009 0.3907 89 0.0003 0.4632 90 0.0005 0.3701 91 0.0003 92 0.3499 93 0.0045 >10 94 0.001 >10 95 0.0015 96 0.0001 0.1667 human CB2 EC50 human CB1 EC50 [µM] [µM] 97 0.0001 0.0623 98 0.0001 0.098 99 0.0002 0.4973 100 0.0001 0.11 101 0.0001 >10 102 0.0006 >10 103 0.0004 0.4147 104 0.0009 >10 105 0.0065 >10 106 0.0048 >10 107 0.2838 108 0.0003 >10 109 0.0005 >10 110 0.0002 0.2503 111 0.0002 0.1366 112 0.0001 0.0047 113 0.0002 0.2013 114 0.0004 >10 115 0.0004 >10 116 0.003 >10 117 0.0002 >10 human CB2 EC50 human CB1 EC50 [µM] [µM] 118 0.0009 >10 119 0.0003 0.091 120 0.0007 0.1812 121 0.0003 >10 122 0.0013 >10 123 0.0008 0.3059 124 0.0003 0.2759 125 0.0019 >10 126 0.0003 0.4964 127 0.0004 >10 128 0.0004 >10 129 0.0001 0.6702 130 0.0005 0.5644 131 0.0001 >10 132 0.0007 >10 133 0.0044 >10 134 0.0003 0.2341 135 0.0004 1.397 136 0.0002 >10 137 0.0182 >10 138 0.0004 >10 human CB2 EC50 human CB1 EC50 [µM] [µM] 139 0.0003 >10 140 0.0001 >10 141 0.0005 >10 142 0.0002 >10 143 0.0001 >10 144 0.0004 0.1227 145 0.0002 2.2486 146 0.0005 >10 147 0.0003 0.209 148 0.0004 >10 149 0.0174 >10 150 0.0363 >10 151 0.0014 >10 152 0.0105 >10 153 0.0119 >10 154 0.0025 >10 155 0.003 >10 156 0.0056 >10 157 0.0001 >10 158 0.2536 >10 159 0.0358 >10 human CB2 EC50 human CB1 EC50 [µM] [µM] 160 0.0007 >10 161 0.0825 >10 162 0.0277 >10 163 0.0055 >10 164 0.0008 >10 165 0.0535 >10 166 0.018 >10 167 0.0038 >10 168 0.0094 >10 169 0.1988 >10 170 0.1937 >10 171 0.0542 >10 172 0.0041 >10 173 0.0003 >10 174 0.002 >10 175 0.0015 >10 176 0.0005 2.0022 177 0.0011 >10 178 0.0009 1.8873 179 0.002 >10 180 0.0528 >10 human CB2 EC50 human CB1 EC50 [µM] [µM] 181 0.0594 >10 182 0.0139 >10 183 0.0042 >10 184 0.1124 >10 185 0.0268 >10 186 0.0003 0.1374 187 0.0008 0.1191 188 0.001 >10 189 0.0332 >10 190 0.0726 >10 191 0.1734 >10 192 0.022 >10 193 0.5929 >10 194 0.2846 >10 195 0.4671 >10 196 0.1188 >10 197 0.2574 >10 198 0.0128 1.7086 199 0.183 >10 200 0.1782 >10 201 0.0657 >10 human CB2 EC50 human CB1 EC50 [µM] [µM] 202 0.0868 >10 203 0.0531 >10 204 0.0005 >10 205 0.0122 >10 206 0.0113 >10 207 0.068 >10 208 0.0092 >10 209 0.016 >10 210 0.0167 >10 211 0.0986 >10 212 0.022 >10 213 0.0596 >10 214 0.0094 >10 215 0.0247 >10 216 0.0104 >10 217 0.0033 >10 218 0.0005 >10 219 0.0329 >10 220 0.0047 >10 221-a 0.003 1.8045 221-b 0.007 0.8526 human CB2 EC50 human CB1 EC50 Example [µM] [µM] 222-a 0.0008 0.8939 222-b 0.0052 >10 223-a 0.0004 0.2412 223-b 0.003 0.2461 224-a 0.0011 0.8986 224-b 0.0064 >10 225-a 0.0291 >10 225-b 0.1748 >10 226-a 0.057 >10 226-b 0.2326 >10 227-a 0.0187 >10 227-b 0.0435 >10 228-a 0.0018 >10 228-b 0.0033 >10 229-a 0.0304 >10 229-b 0.0374 >10 230-a 0.0027 >10 230-b 0.0136 >10 β-Arrestin translocation PathHunter™ (DiscoveRx) PathHunter™ β-arrestin CHO-K1 CNR1 cell line (catalog number #93-0200C2) and the βarrestin CHO-K1 CNR2 cell line (catalog number #93-0706C2) were purchased from DiscoveRx Corporation. The cell line was engineered to express the β-galactosidase EA fragment fused to β-arrestin and the k complementary peptide fused to the target receptor. The PathHunter™ protein complementation assay (DiscoveRx ation #93- 0001) was performed ing to the manufacturer’s protocol. Assay plates were seeded containing 7500 (CNR1) and 10000 (CNR2) cells in 384 well plates (Corning Costar #3707, white, clear bottom) in 20µL cell plating reagent 2 (Discoverx #93-0563R2A).

After incubation at 37 °C (5% CO2, 95% relative humidity) overnight, 5 µl of test compound was added (1% final DMSO concentration) and the incubation continued at 30 °C for 90 min. Detection reagent (12 µl) was then added and the incubation continued at room ature for 60 min. Plates were then analyzed for a chemiluminescent signal using a Victor 3V reader (Perkin Elmer).

Example A Film coated tablets containing the following ingredients can be manufactured in a conventional manner: Ingredients Per tablet Kernel: Compound of a (I) 10.0 mg 200.0 mg Microcrystalline cellulose 23.5 mg 43.5 mg Lactose hydrous 60.0 mg 70.0 mg Povidone K30 12.5 mg 15.0 mg Sodium starch glycolate 12.5 mg 17.0 mg ium stearate 1.5 mg 4.5 mg (Kernel Weight) 120.0 mg 350.0 mg Film Coat: Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg Polyethylene glycol 6000 0.8 mg 1.6 mg Talc 1.3 mg 2.6 mg Iron oxide (yellow) 0.8 mg 1.6 mg Titan dioxide 0.8 mg 1.6 mg The active ient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is then mixed with sodium starch glycolate and magnesium stearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aq. solution / suspension of the above mentioned film coat.

Example B Capsules containing the following ients can be manufactured in a conventional Ingredients Per capsule Compound of formula (I) 25.0 mg Lactose 150.0 mg Maize starch 20.0 mg Talc 5.0 mg The components are sieved and mixed and filled into capsules of size 2.

Example C Injection solutions can have the following ition: Compound of formula (I) 3.0 mg Polyethylene glycol 400 150.0 mg Acetic acid q.s. ad pH 5.0 Water for injection solutions ad 1.0 ml The active ingredient is dissolved in a mixture of Polyethylene glycol 400 and water for injection (part). The pH is adjusted to 5.0 by addition of acetic acid. The volume is adjusted to 1.0 ml by on of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.

Claims (30)

Claims

1. A compound of formula (I) R1 A N N R2 (I) wherein 5 A is alkyl, hydroxyalkyl, -CH2C(O)-, , -SO2- or absent; R1 is hydrogen, alkyl, haloalkyl, hydroxyl, alkoxy, haloalkoxy, phenyl, halophenyl, alkoxyphenyl, kylphenyl, koxyphenyl, (halo)(haloalkyl)phenyl, cyanophenyl, hydroxyalkoxyphenyl, alkylsulfonylphenyl, alkylsulfonylaminophenyl, cyano, cycloalkyl, lkylalkoxy, amino, 10 (alkylsulfonyl)(alkyl)[1,2,4]triazolyl, (halo)(dialkylamino)pyridinyl, (alkyl)(oxy)pyridinyl, nitro-benzo[1,2,5]oxadiazolylaminopyridinyl, heterocyclyl, alkylheterocyclyl, hydroxyheterocyclyl, alkylheterocyclyl, heteroaryl, haloheteroaryl, alkylheteroaryl, cycloalkylheteroaryl or haloalkylheteroaryl, wherein heterocyclyl is a three to eight membered 15 carbocyclic ring comprising at least one nitrogen or oxygen atom, and n heteroaryl is pyridinyl, pyrazolyl, oxadiazolyl, furazanyl, tetrazolyl or triazolyl; R2 is halogen or -NR3R4 or -OR5; one of R3 and R4 is hydrogen or alkyl and the other one is alkyl or cycloalkyl; 20 or R3 and R4 together with the nitrogen atom to which they are attached form heterocyclyl or substituted heterocyclyl, wherein cyclyl is morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, 2-oxaazaspiro[3.3]heptyl, azetidinyl, thiazolidinyl, thiomorpholinyl, dioxothiomorpholinyl, oxazepanyl, 2-oxa azaspiro[3.4]octyl, 6-oxaazaspiro[3.3]heptyl, 2-oxaaza-spiro[3.4]octyl, 25 isoxazolidinyl, inyl, dioxoisothiazolidinyl or oxopyrolidinyl and wherein substituted heterocyclyl is heterocyclyl substituted with one to four substituents independently selected from alkyl, halogen, hydroxyl, alkoxy, hydroxyalkyl, carboxyl, alkoxyalkyl, cyano, mino, dialkylamino, alkylcarbonylamino, alkylcarbonyl(alkylamino), phenyl, alkoxycarbonyl, lkyl, alkylpyrazolyl or alkylisoxazolyl; R5 is alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl or oxetanyl; or a ceutically acceptable salt or ester thereof; 5 with the proviso that 3-[(2-chlorophenyl)methyl](1,1-dimethylethyl)(4- morpholinyl)-3H-1,2,3-triazolo[4,5-d]pyrimidine and N-cyclopropyl(1,1- dimethylethyl)(phenylmethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidinamine are excluded.

2. A nd according to claim 1, wherein A is alkyl or yalkyl. 10

3. A nd according to claim 1 or 2, wherein A is -CH2-, -CH2CH 2-, -CH(CH 3)- or -CH(OH)CH2-.

4. A compound according to any one of claims 1 to 3, wherein R1 is hydrogen, alkyl, haloalkyl, hydroxyl, alkoxy, phenyl, halophenyl, alkoxyphenyl, kylphenyl, haloalkoxyphenyl, alkylsulfonylphenyl, cyanophenyl, cycloalkyl, alkylheterocyclyl, 15 hydroxyheterocyclyl, heteroaryl, cycloalkylheteroaryl, haloheteroaryl or alkylheteroaryl, wherein heterocyclyl is a carbocyclic ring ning at least one nitrogen atom and wherein heteroaryl is pyridinyl, pyrazolyl, oxadiazolyl, tetrazolyl or furazanyl.

5. A compound according to any one of claims 1 to 4, wherein R1 is haloalkyl, phenyl, 20 halophenyl, haloalkylphenyl, cyanophenyl, alkylsulfonylphenyl, lkyl, heteroaryl, cycloalkylheteroaryl, haloheteroaryl or alkylheteroaryl, wherein heteroaryl is pyridinyl, pyrazolyl, oxadiazolyl, tetrazolyl or furazanyl.

6. A compound according to any one of claims 1 to 5, wherein R1 is phenyl, cyclohexyl, rophenyl, pyridinyl, chloropyridinyl, dichloropyridinyl, 25 trifluoromethyl, chlorodifluorophenyl, trifluoromethylphenyl, cyanophenyl, phenyl, methylsulfonylphenyl, methyltetrazolyl, methylfurazanyl or cyclopropyltetrazolyl.

7. A compound according to any one of claims 1 to 6, wherein one of R3 and R4 is hydrogen or ethyl and the other one is ethyl or cyclohexyl.

8. A compound according to any one of claims 1 to 6, wherein R3 and R4 together with 30 the nitrogen atom to which they are attached form heterocyclyl or substituted heterocyclyl, wherein heterocyclyl is dinyl, pyrrolidinyl, azetidinyl or 2-oxa azaspiro[3.3]heptyl, and n substituted heterocyclyl is heterocyclyl substituted with one to four tuents independently selected from alkyl, halogen, hydroxyl, hydroxyalkyl and alkoxyalkyl.

9. A compound according to any one of claims 1 to 6, n R3 and R4 together with 5 the nitrogen atom to which they are attached form difluoropiperidinyl, difluoropyrrolidinyl, difluoroazetidinyl, (methyl)(hydroxyl)azetidinyl, hydroxypyrrolidinyl, hydroxymethylpyrrolidinyl, tetrafluoropyrrolidinyl, ymethylpyrrolidinyl, (hydroxyl)(hydroxymethyl)pyrrolidinyl, (methyl)(hydroxyl)pyrrolidinyl or 6-azaspiro[3.3]heptyl.

10 10. A compound according to any one of claims 1 to 9, wherein R5 is , ethyl, isopropyl, pentyl, cyclobutyl, cyclopentyl, cyclopropylmehtyl, cyclopropylethyl, trifluoropropyl or oxetanyl.

11. A compound according to any one of claims 1 to 10 selected from 5-tert-butyl(2-chlorobenzyl)(piperidinyl)-3H-[1,2,3]triazolo[4,5- 15 d]pyrimidine; 5-tert-butyl(2-chlorobenzyl)(4,4-difluoropiperidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-butyl(2-chlorobenzyl)(4-methylpiperazinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 20 5-tert-butyl(2-chlorobenzyl)(pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5-tert-butyl(2-chlorobenzyl)(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-butyl(2-chlorobenzyl)-N-ethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinamine; 25 5-tert-butyl(2-chlorobenzyl)-N-cyclohexyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin amine; 5-tert-butyl(2-chlorobenzyl)-N,N-diethyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin amine; 6-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)oxa 30 azaspiro[3.3]heptane; 7-(azetidinyl)tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5-tert-butyl(2-chlorobenzyl)(3,3-difluoroazetidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)azetidin- 3-ol; 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylazetidinol; 5-tert-butyl(2-chlorobenzyl)(3-methoxyazetidinyl)-3H-[1,2,3]triazolo[4,5- 10 d]pyrimidine; (2S,6R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- methylmorpholine; 4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylmorpholine; 15 (4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)morpholinyl)methanol; 3-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin azolidine; 4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin 20 yl)thiomorpholine; 5-tert-butyl(2-chloro-benzyl)(1,1-dioxo-1λ6-thiomorpholinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-1,4- oxazepane; 25 4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-2,2- dimethylmorpholine; 4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)-3,3- dimethylmorpholine; 5-tert-butyl(2-chlorobenzyl)((2R,5R)-2,5-dimethylpyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinol; 5 (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinol; 5-tert-butyl(2-chlorobenzyl)(3-methoxypyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5-tert-butyl(2-chlorobenzyl)(2,2-dimethylpyrrolidinyl)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-butyl(2-chlorobenzyl)(2-methylpyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; ert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)oxa azaspiro[3.4]octane; 15 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)piperidin- 4-ol; (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)piperidinol; (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin 20 yl)piperidinol; 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)oxa azaspiro[3.3]heptane; (S)tert-butyl(2-chlorobenzyl)(3-fluoropyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 25 (R)-(1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin rolidinyl)methanol; (S)-(1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinyl)methanol; 2-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)morpholine; ert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)isoxazolidine; 5 7-(aziridinyl)tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; (R)tert-butyl(2-chlorobenzyl)(3-fluoropyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-butyl(2-chlorobenzyl)(3,3,4,4-tetrafluoropyrrolidinyl)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidine; (R)tert-butyl(2-chlorobenzyl)(2-(methoxymethyl)pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (S)tert-butyl(2-chlorobenzyl)(2-(methoxymethyl)pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 15 (2S,4S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 4-fluoropyrrolidinecarbonitrile; 5-tert-butyl(2-chloro-benzyl)(1,1-dioxo-1λ6-isothiazolidin -3H- [1,2,3]triazolo[4,5-d]pyrimidine; (4-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin 20 yl)morpholinyl)methanol; (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinecarbonitrile; (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinecarbonitrile; 25 (2S,3S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 2-(hydroxymethyl)pyrrolidinol; (2S,3R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 2-(hydroxymethyl)pyrrolidinol; 5-tert-Butyl(2-chloro-benzyl)(2-oxaaza-spiro[3.4]octyl)-3H- ]triazolo[4,5-d]pyrimidine; 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl] methyl-pyrrolidinol; 5 (3R,4R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidine-3,4-diol; (3S,4R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidine-3,4-diol; 4-(5-tert-butyl(4-methoxybenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin 10 yl)morpholine; 4-(5-tert-butyl-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)morpholine; 5-tert-Butyl(2-chlorofluoro-benzyl)morpholinyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(4-methoxy-benzyl)-3H- 15 [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)ethyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methoxy-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 20 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl]-ethanol; 5-tert-Butylcyclohexylmethyl(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3-chloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- 25 ]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(4-chloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2,3-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2,4-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2,5-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5 5-tert-Butyl(2,6-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 15 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,2,2-trifluoro-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-4,5-difluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- 20 [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-3,6-difluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- ]triazolo[4,5-d]pyrimidine; 3-(2-Bromo-benzyl)tert-butyl(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 25 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-trifluoromethyl-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methoxy-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-trifluoromethoxy-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin ylmethyl]-benzonitrile; 5 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)phenethyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl]phenyl-ethanone; 5-tert-Butyl[(R)(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl[(S)(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl]phenyl-ethanol; 15 5-tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- ]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)oxetanyl-3H-[1,2,3]triazolo[4,5- 20 d]pyrimidine; [5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidinyl]- (2-chloro-phenyl)-methanone; )[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]hydroxymethyl-pyrrolidinol; 25 {(R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- 4,4-difluoro-pyrrolidinyl}-methanol; (R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- 4,4-difluoro-pyrrolidinol; -Butyl(2,6-dichlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5 5-tert-Butyl(3-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2,5-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,6-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)- 10 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(4-methyl-furazanylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-methyl-[1,2,4]oxadiazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 15 5-tert-Butyl[2-(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl[2-(3-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl[2-(4-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- 20 [1,2,3]triazolo[4,5-d]pyrimidine; (S)[5-tert-Butyl(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- idinol; 5-tert-Butyl(2-chloro-benzenesulfonyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 25 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(R)-tetrahydro-furanyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(S)-tetrahydro-furanyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl](2-chloro-phenyl)-ethanone; 5-tert-Butyl(2,3-dichlorofluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5 -Butyl(3,3-difluoro-pyrrolidinyl)(2-methanesulfonyl-benzyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-pyridinyl-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-methyl-oxetanylmethyl)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl](3-chloro-phenyl)-ethanone; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl](4-chloro-phenyl)-ethanone; 15 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl]pyridinyl-ethanone; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl]pyridinyl-ethanone; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,3,6-trichloro-benzyl)-3H- 20 [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chlorotrifluoromethyl-benzyl)(3,3-difluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-pyridinyl-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 25 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-pyridinyl-ethyl)-3H- ]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2,3-dichlorotrifluoromethyl-benzyl)(3,3-difluoro-pyrrolidin yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,4-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(1,1-dioxo-1λ6-thietanyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5 -Butyl(3,3-difluoro-pyrrolidinyl)(1,1-dioxo-tetrahydro-1λ6-thiophen- 3-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl]pyridinyl-ethanone; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(5-methyl-[1,3,4]oxadiazol 10 ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(5-methyl-[1,2,4]oxadiazol yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 15 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(1-methyl-1H-tetrazolylmethyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methyl-2H-[1,2,4]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(5-methanesulfonylmethyl-4H- 20 [1,2,4]triazolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; {3-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin ylmethyl]chloro-pyridinyl}-dimethyl-amine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-trifluoromethyl-1H-pyrazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 25 (S)[5-tert-Butyl(4-methyl-furazanylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(3-methyl-[1,2,4]oxadiazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(3-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(3,6-dichloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; 5 (S)[5-tert-Butyl(2-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2,3-dichloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinol; [5-tert-Butyl(2-trifluoromethyl-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 10 7-yl]-pyrrolidinol; (S)[5-tert-Butyl(2-methanesulfonyl-benzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,5-dimethyl-2H-pyrazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 15 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-methyl-3H-[1,2,3]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(4,5-dimethyl-4H-[1,2,4]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(3,3-difluoro-pyrrolidinyl)(2-methyloxy-pyridinylmethyl)- 20 3H-[1,2,3]triazolo[4,5-d]pyrimidine; (S)[5-tert-Butyl(3,4-dichloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(5-methyl-[1,2,4]oxadiazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; 25 (S)[5-tert-Butyl(5-methyl-[1,3,4]oxadiazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2-methyl-2H-[1,2,4]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol; 5 (S)[5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2,5-dimethyl-2H-pyrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(3-trifluoromethyl-[1,2,4]oxadiazol 10 ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)(3,3-difluoro-pyrrolidin yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; {5-tert-Butyl[2-(7-nitro-benzo[1,2,5]oxadiazolylamino)-pyridin ylmethyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl}-pyrrolidinol; 15 (2S,3S)[5-tert-Butyl(4-methoxy-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]hydroxymethyl-pyrrolidinol; (S)[5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2,5-dimethyl-2H-[1,2,4]triazolylmethyl)-3H- 20 [1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(2-methyloxy-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; -Butyl(3,3-difluoro-pyrrolidinyl)(2,5-dimethyl-2H-[1,2,4]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 25 (2S,3S)[5-tert-Butyl(4-methyl-furazanylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]hydroxymethyl-pyrrolidinol; )[5-tert-Butyl(3-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; 5 (2S,3S)[5-tert-Butyl(2-methanesulfonyl-benzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(2-methyl-2H-[1,2,4]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl]hydroxymethyl-pyrrolidinol; (2S,3S)[5-tert-Butyl(2-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]hydroxymethyl-pyrrolidinol; 15 5-tert-Butyl(4-methyl-furazanylmethyl)(3,3,4,4-tetrafluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3-methyl-[1,2,4]oxadiazolylmethyl)(3,3,4,4-tetrafluoropyrrolidinyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(5-methyl-[1,3,4]oxadiazolylmethyl)(3,3,4,4-tetrafluoro- 20 pyrrolidinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)(3,3,4,4-tetrafluoro-pyrrolidin yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)(3,3,4,4-tetrafluoropyrrolidinyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 25 5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)(3,3,4,4-tetrafluoropyrrolidinyl )-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(4-methyl-furazanylmethyl)(2-oxaaza-spiro[3.3]heptyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3-methyl-[1,2,4]oxadiazolylmethyl)(2-oxaazaspiro [3.3]heptyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(5-methyl-[1,3,4]oxadiazolylmethyl)(2-oxaazaspiro [3.3]heptyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5 5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)(2-oxaaza-spiro[3.3]hept yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(1-cyclopropyl-1H-tetrazolylmethyl)(2-oxaazaspiro [3.3]heptyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(4,5-dimethyl-4H-[1,2,4]triazolylmethyl)(2-oxaaza- 10 spiro[3.3]heptyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3-methyl-3H-[1,2,3]triazolylmethyl)(2-oxaazaspiro [3.3]heptyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-methanesulfonyl-benzyl)(2-oxaaza-spiro[3.3]heptyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 15 5-tert-Butyl(3-chloro-pyridinylmethyl)(2-oxaaza-spiro[3.3]heptyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinone; 5-tert-Butyl(2-chloro-benzyl)(3,3-dimethyl-pyrrolidinyl)-3H- 20 [1,2,3]triazolo[4,5-d]pyrimidine; {1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-methyl-amine; tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-dimethyl-amine; 25 N-{(S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-acetamide; N-{(R)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl]-pyrrolidinyl}-acetamide; N-{1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-N-methyl-acetamide; 5-tert-Butyl(2-chloro-benzyl)(3-phenyl-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5 N-{1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-N-ethyl-acetamide; 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- azetidinecarboxylic acid methyl ester; 5-tert-Butyl(2-chloro-benzyl)(3-methyl-pyrrolidinyl)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidine; C-{(S)[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinyl}-methylamine; 5-tert-Butyl(2-chloro-benzyl)[2-(1-methyl-1H-pyrazolyl)-pyrrolidinyl]- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 15 5-tert-Butyl(2-chloro-benzyl)[2-(2-methyl-2H-pyrazolyl)-pyrrolidinyl]- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)[2-(3-methyl-isoxazolyl)-pyrrolidinyl]-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)[2-(3-methyl-[1,2,4]oxadiazolyl)-pyrrolidin 20 yl]-3H-[1,2,3]triazolo[4,5-d]pyrimidine; ert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]- pyrrolidinol; 5-tert-Butyl(2-chloro-benzyl)cyclobutoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)(oxetanyloxy)-3H-[1,2,3]triazolo[4,5- 25 d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)methoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine; -Butyl(2-chloro-benzyl)ethoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)isopropoxy-3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)cyclopropylmethoxy-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)(1-cyclopropyl-ethoxy)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5 5-tert-Butyl(2-chloro-benzyl)cyclopentyloxy-3H-[1,2,3]triazolo[4,5- d]pyrimidine; -Butyl(2-chloro-benzyl)(2,2-dimethyl-propoxy)-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)(2,2,2-trifluoromethyl-ethoxy)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)((S)-2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-benzyl)((R)-2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 15 (3S)(3-benzyltert-butyl-triazolo[4,5-d]pyrimidinyl)pyrrolidinol; 1-(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinol; (R)(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)pyrrolidinol; 20 1-(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)pyrrolidinol; (5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol; (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) 25 methylpyrrolidinol; (S)(5-tert-butyl(2-(trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)methylpyrrolidinol; (R)(5-tert-butyl(2-(trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)methylpyrrolidinol; (S)(5-tert-butyl(2-(methylsulfonyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)methylpyrrolidinol; (5-tert-butyl(2-(methylsulfonyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)methylpyrrolidinol; 5 (S)(5-tert-butyl((3-chloropyridinyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (R)(5-tert-butyl((3-chloropyridinyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (S)(5-tert-butyl((5-methyl-1,3,4-oxadiazolyl)methyl)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol; (R)(5-tert-butyl((5-methyl-1,3,4-oxadiazolyl)methyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol; (S)(5-tert-butyl((3-methyl-1,2,4-oxadiazolyl)methyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol; 15 (R)(5-tert-butyl((3-methyl-1,2,4-oxadiazolyl)methyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol; (S)(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl)methylpyrrolidinol; (R)(5-tert-butyl((1-methyl-1H-tetrazolyl)methyl)-3H-[1,2,3]triazolo[4,5- 20 d]pyrimidinyl)methylpyrrolidinol; (S)(5-tert-butyl((4-methyl-1,2,5-oxadiazolyl)methyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol; (R)(5-tert-butyl((4-methyl-1,2,5-oxadiazolyl)methyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol; 25 (S)(5-tert-butyl(3,3,3-trifluoropropyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin methylpyrrolidinol; (R)(5-tert-butyl(3,3,3-trifluoropropyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)methylpyrrolidinol; (S)(5-tert-butyl((1-cyclopropyl-1H-tetrazolyl)methyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol; and (R)(5-tert-butyl((1-cyclopropyl-1H-tetrazolyl)methyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidinyl)methylpyrrolidinol. 5

12. A compound according to any one of claims 1 to 11 selected from 5-tert-Butyl(2-chlorobenzyl)(4,4-difluoropiperidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chlorobenzyl)(3,3-difluoropyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 10 5-tert-Butyl(2-chlorobenzyl)(3,3-difluoroazetidinyl)-3H-[1,2,3]triazolo[4,5- midine; 1-(5-tert-Butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylazetidinol; (S)(5-tert-Butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin 15 yl)pyrrolidinol; (R)-(1-(5-tert-Butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin yl)pyrrolidinyl)methanol; 5-tert-Butyl(2-chlorobenzyl)(3,3,4,4-tetrafluoropyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 20 tert-Butyl(2-chlorobenzyl)(2-(methoxymethyl)pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (2S,3S)(5-tert-Butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)- 2-(hydroxymethyl)pyrrolidinol; 1-[5-tert-Butyl(2-chloro-benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl] 25 -pyrrolidinol; 5-tert-Butylcyclohexylmethyl(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2,6-dichloro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)pyridinylmethyl-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2,2,2-trifluoro-ethyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(2-chloro-3,6-difluoro-benzyl)(3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-trifluoromethyl-benzyl)-3H- 10 [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin ylmethyl]-benzonitrile; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)phenethyl-3H-[1,2,3]triazolo[4,5- d]pyrimidine; 15 5-tert-Butyl[(R)(2-chloro-phenyl)-ethyl](3,3-difluoro-pyrrolidinyl)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; 2-[5-tert-Butyl(3,3-difluoro-pyrrolidinyl)-[1,2,3]triazolo[4,5-d]pyrimidin yl]phenyl-ethanol; -Butyl(3-chloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)-3H- 20 [1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,6-dichloro-pyridinylmethyl)(3,3-difluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(1-methyl-1H-tetrazolylmethyl)- 2,3]triazolo[4,5-d]pyrimidine; 25 5-tert-Butyl(3,3-difluoro-pyrrolidinyl)(2-methyl-2H-[1,2,4]triazol ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine; (S)[5-tert-Butyl(4-methyl-furazanylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(3-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- midinyl]-pyrrolidinol; [5-tert-Butyl(2-chloro-pyridinylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; 5 (S)[5-tert-Butyl(2-methanesulfonyl-benzyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(1-methyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- d]pyrimidinyl]-pyrrolidinol; (S)[5-tert-Butyl(1-cyclopropyl-1H-tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5- 10 d]pyrimidinyl]-pyrrolidinol; 5-tert-Butyl(4-methyl-furazanylmethyl)(3,3,4,4-tetrafluoro-pyrrolidinyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 5-tert-Butyl(3-chloro-pyridinylmethyl)(2-oxaaza-spiro[3.3]heptyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidine; 15 5-tert-Butyl(2-chloro-benzyl)((R)-2,2,2-trifluoromethyl-ethoxy)-3H- [1,2,3]triazolo[4,5-d]pyrimidine; (S)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol; (R)(5-tert-butyl(2-chlorobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) 20 methylpyrrolidinol; (S)(5-tert-butyl(2-(trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)methylpyrrolidinol; (R)(5-tert-butyl(2-(trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)methylpyrrolidinol; 25 (S)(5-tert-butyl(2-(methylsulfonyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)methylpyrrolidinol; and (R)(5-tert-butyl(2-(methylsulfonyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 7-yl)methylpyrrolidinol.

13. A compound according to claim 1, which is (S)[5-tert-Butyl(2-chloro-benzyl)- 3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol.

14. A nd according to claim 1, which is 5-tert-Butyl(2-chloro-benzyl) (3,3,4,4-tetrafluoro-pyrrolidinyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine. 5

15. A compound according to claim 1, which is 5-tert-Butyl(2-chloro-3,6-difluorobenzyl )(3,3-difluoro-pyrrolidinyl)-3H-[1,2,3] triazolo[4,5-d]pyrimidine.

16. A compound according to claim 1, which is 5-tert -Butyl(3-chloro-pyridin ylmethyl)(3,3-difluoro-pyrrolidinyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine.

17. A compound according to claim 1, which is (S)[5-tert -Butyl(4-methyl-furazan- 10 3-ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol.

18. A compound according to claim 1, which is (S)[5-tert -Butyl(3-chloro-pyridin- 2-ylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol.

19. A compound according to claim 1, which is (S)[5-tert -Butyl(2-chloro-pyridin- thyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol. 15

20. A compound according to claim 1, which is (S)[5-tert -Butyl(1-methyl-1H- tetrazolylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl]-pyrrolidinol.

21. A compound according to claim 1, which is (R)(5-tert-butyl((1-methyl-1H- olyl)methyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl)pyrrolidinol.

22. A compound according to claim 1, which is (S)(5-tert-butyl(2- 20 (trifluoromethyl)benzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidinyl) methylpyrrolidinol.

23. A s for the preparation of a compound ing to any one of claims 1 to 22 comprising: (a) the reaction of a compound of formula (A), a tautomer thereof or a mixture of 25 tautomers thereof in the ce of a halogenation reagent and optionally with a base; or (b) the reaction of a compound of formula (B) 5 (B) in the presence of NHR3R4 and optionally with a base; wherein A, R1, R3 and R4 are defined according to any one of claims 1 to 10.

24. A compound according to any one of claims 1 to 22, when manufactured according to a process of claim 23. 10

25. A compound according to any one of claims 1 to 23 for use as therapeutically active substance.

26. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 23 and a eutically inert carrier.

27. The use of a nd according to any one of claims 1 to 23 for the preparation of 15 a medicament for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, diabetes us, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, 20 ulonephropathy, cardiomyopathy, heart failure, dial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, neurodegeneration, stroke, transient ischemic attack or uveitis.

28. A compound according to any one of claims 1 to 23 for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, ic pathy, 5 glaucoma, diabetes mellitus, inflammation, inflammatory bowel e, ischemiareperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, 10 hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or , regulation of bone mass, neurodegeneration, stroke, transient ischemic attack or uveitis.

29. A pharmaceutical composition ing to claim 26 substantially as herein bed with reference to any example thereof.

30. A process according to claim 23 substantially as herein bed with reference to 15 any example thereof.